Introduction {#s1}
============

The single-layered intestinal epithelium provides an important physical barrier that critically contributes to intestinal homeostasis ([@bib48]). Dysfunction of intestinal epithelial cells (IECs) leading to increased epithelial permeability is associated with intestinal diseases such as inflammatory bowel disease (IBD) and colorectal cancer (CRC) ([@bib61]; [@bib55]; [@bib19]). IBD is related to polymorphisms in various IBD susceptibility genes ([@bib35]; [@bib62]), and numerous genetic alterations in key cellular pathways that underlie CRC have been identified ([@bib16]). However, the role of post-transcriptional modifications in the regulation of IBD and CRC development is still poorly understood.

Alternative splicing of pre-mRNAs (AS) is a common posttranscriptional modification that is estimated to occur in 92--94% of human genes ([@bib66]; [@bib47]). AS permits generation of protein isoforms with related, distinct or sometimes even opposing functions ([@bib65]). Moreover, certain isoforms influence cancer progression ([@bib5]) or are associated with autoimmune and inflammatory disorders ([@bib59]; [@bib33]). While alterations of mRNA splicing have been reported in human colorectal cancer (CRC) ([@bib18]; [@bib75]) and IBD ([@bib20]; [@bib41]), the consequences of deregulated AS for intestinal homeostasis and disease development are largely unexplored.

Epithelial splicing regulatory protein 1 (*ESRP1*), which is exclusively expressed in epithelial cells, was identified in a cDNA expression screen for factors that promote the epithelial pattern of *FGFR2* (Fibroblast Growth Factor Receptor 2) splicing. *ESRP1* was also found to regulate the AS of *CD44* and other genes ([@bib69]). ESRP1 is negatively regulated by mesenchymal transcription factors such as SNAIL, ZEB1 and ZEB2 ([@bib50]; [@bib54]; [@bib52]). Recently, *ESRP1* has been reported to act as a tumor suppressor by negatively regulating epithelial-to-mesenchymal transition (EMT) and the metastatic potential of human breast cancer cell lines, via the splicing of different isoforms of *CD44* or *EXO70* ([@bib39]). ESRP1 can suppress cancer cell motility in head and neck carcinoma cell lines ([@bib25]) and ESRP1 protein expression is a favorable prognostic factor in pancreatic cancer ([@bib60]). However, ESRP1 may also promote lung metastasis of orthotopically transplanted breast cancer cells by generating *CD44* isoforms independently of EMT ([@bib70]). Yet, the contribution of ESRP1 to intestinal integrity and function is poorly investigated. Importantly, the lack of viable animal models so far has precluded analyzing the role of ESRP1-mediated AS for intestinal disease in vivo.

Here, we used a novel mutant allele of *Esrp1* called *Triaka* to investigate the function of ESRP1 in the intestine. We found that *Esrp1^Triaka^* (later referred to as *Triaka*) leads to reduced ESRP1 function causing distinct alterations in the mRNA splicing pattern in colonic IECs (cIECs) of *Triaka* compared with wild-type (WT) animals. These changes in several transcript isoforms do not alter intestinal histomorphology, yet they are associated with increased intestinal permeability in *Triaka* mice. In addition, *Triaka* mice show alterations in distinct models of intestinal disease. Mechanistically, this phenotype can be ascribed, in part, to changes in the relative frequency of specific *Gpr137* splicing isoforms in *Triaka* cIECs. This affects the survival and function of cIEC by altering the Wnt signaling pathway in *Triaka* mice. In humans, *ESRP1* transcript levels are downregulated in inflamed compared with non-inflamed biopsies from IBD patients. Furthermore, ESRP1 expression is gradually lost during the adenoma to carcinoma sequence in CRC, and loss of ESRP1 protein expression in CRC tumors negatively correlates with patient survival. Moreover, the ratio of specific *GPR137* isoforms is different in tumor versus normal intestinal tissue, and expression of a specific *ESRP1*-dependent *GPR137* isoform predicts CRC patient survival.

Together, these data indicate an important role for ESRP1 in intestinal disease in humans and mice.

Results {#s2}
=======

*Esrp1^Triaka^* reduces mRNA splicing function {#s2-1}
----------------------------------------------

To study the role of ESRP1 in the intestinal epithelium, we used a novel mutant allele of *Esrp1* called *Triaka* that was identified in an *N*-ethyl-*N*-nitrosourea genetic screen. The *Triaka* point mutation results in a methionine-to-valine substitution at the amino acid position 161 (M161V) of ESRP1, a residue conserved in several species ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). *Triaka* animals develop overtly normal (see also Materials and methods), which allows investigation of the physiological role of *Esrp1* in adults. This is in contrast to the recently published *Esrp1*^-/-^ or skin epithelial-specific *Esrp1*-deficient animals that are neonatal lethal ([@bib3]). We first utilized a previously described in vitro reporter system to characterize the effect of *Esrp1^Triaka^* on the splicing of known ESRP1-regulated transcripts ([@bib5]). Using this system based on luciferase expression, we found that WT ESRP1 protein led to a 2.4 and 10.9 fold increase of *Cd44* variable exon v5 (*Cd44v5*) and *Fgfr2* variable exon IIIb (*Fgfr2-*IIIb) inclusion, respectively, compared to control. This was in line with earlier reports ([@bib5]; [@bib69]). ESRP1*^Triaka^* however showed reduced levels of *Cd44v5* and *Fgfr2-*IIIb inclusion, with 1.8 and 3.3 fold induction, respectively ([Figure 1A and B](#fig1){ref-type="fig"}). This variation in the extent of in vitro splicing of *Cd44* versus *Fgfr2* by ESRP1*^Triaka^* likely related to the fact that *Esrp1*-regulated splicing events show distinct sensitivity to *Esrp1* loss ([@bib69]; [@bib3]).

![*Esrp1^Triaka^* leads to altered mRNA splicing and reduced epithelial cell proliferation.\
To quantify exon splicing, HEK-293 cells were co-transfected with a vector encoding *Esrp1*^WT^ or *Esrp1^Triaka^* or an empty control (CTRL) vector and with an exon trap construct containing (**A**) *Cd44* variant 5 (*Cd44v5*) or (**B**) *Ffgr2*-IIIb variable exon. Upper panels in (**A**) and (**B**) show schemes of the respective exon trap constructs. Inclusion of exon *Cd44v5* or *Ffgr2*-IIIb results in luciferase (Luc) expression. Luciferase activity normalized to control vector-transfected cells is shown in the lower panels. Relative expression of (**C**) *Esrp1* and (**D**) *Cd44v4/5* transcripts were measured in CMT-93 cells transduced with inducible vectors encoding *Esrp1*^WT^, *Esrp1^Triaka^*, or a control construct, after treatment with 4-hydroxytamoxifen. (**E**) Proliferation of *Esrp1*^WT^- and *Esrp1^Triaka^*-expressing CMT-93 cells was measured using a WST-1 assay and normalized to control vector-transduced cells. (**F**) Relative expression of *Esrp1* and *Cd44v4/5* transcripts were measured in CMT-93 cells transduced with a vector encoding *Esrp1*^WT^, after induction with 4-hydroxytamoxifen, and correlated. Data represent: Pooled means ± standard error of the mean from (**A and B**) five or (**C--E**) three independent experiments performed in biological triplicates. (**F**) Means measured in technical duplicates (*n* = 22). Statistics: (**A--D**) One-way ANOVA with Bonferroni post-test. (**E**) Two-way ANOVA with Bonferroni post-test. (**F**) Spearman correlation. \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001.](elife-28366-fig1){#fig1}

We then transduced CMT-93 cells with inducible lentiviral encoding *Esrp1*^WT^ or *Esrp1^Triaka^* to assess the effect of the mutation on epithelial cell function. At the same level of overexpression as *Esrp1*^WT^, *Esrp1^Triaka^* led to diminished inclusion of *Cd44v4/5* in CMT-93 cells and reduced cell proliferation ([Figure 1C--E](#fig1){ref-type="fig"}). Of note, *Esrp1*^WT^ transcript levels directly correlated with frequency of *Cd44v4/5* splicing events, suggesting a dose-dependent effect of *Esrp1* expression on *Esrp1*-mediated splicing activity ([Figure 1F](#fig1){ref-type="fig"}). Taken together, these in vitro data indicate that *Esrp1^Triaka^* reduces ESRP1 function, and thereby decreases the proliferative capacity of epithelial cells.

*Esrp1^Triaka^* leads to altered mRNA splicing pattern in vivo {#s2-2}
--------------------------------------------------------------

*Esrp1* has been shown to be epithelial cell-restricted and to be highly expressed in the murine large intestine ([@bib69]). Thus, we next investigated the impact of *Esrp1^Triaka^* on the mRNA splicing pattern of cIECs. RNA sequencing was performed on cIECs isolated from naïve mice. Computational analysis revealed 35 genes for which the relative frequency of splicing isoforms differed in *Esrp1^Triaka^* versus *Esrp1*^WT^ cIECs ([Figure 2A and B](#fig2){ref-type="fig"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). These findings were validated using quantitative reverse-transcription polymerase chain reaction (qPCR) for selected, previously reported ESRP1 target genes, including *Cd44* and *Magi1* ([@bib5]; [@bib69]; [@bib68]), and for novel candidate targets, including *Uap1* and *Gpr137* ([Figure 2C](#fig2){ref-type="fig"}). Functional alterations induced by ESRP1*^Triaka^* were also apparent on the protein level, as expression of CD44 variant 4 (CD44v4)-containing isoforms, but not total CD44, was reduced in colonic sections of *Triaka* versus WT mice ([Figure 2D](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Therefore, these results suggested *Esrp1^Triaka^*-dependent functional changes in mutant mice.

![*Esrp1^Triaka^* alters mRNA splicing patterns in colonic intestinal epithelial cells.\
(**A**) RNA sequencing analysis was performed on colonic intestinal epithelial cells (cIECs) isolated from WT and *Triaka* mice. Dot plot indicating the relative difference in isoform usage for a given transcription start site expressed as Jensen-Shannon divergence and the associated p-values. Analysis was performed through CummeRbund and FDR-adjusted p-value\<0.05 were considered significant. Red and orange dots represent genes with differences in transcript isoforms generated by bona fide alternative splicing (AS) events or by other mechanisms, respectively (*n* = 4 donor mice per group). (**B**) Panel showing the relative frequency of the different isoforms identified as AS events in (**A**) for 36 transcription start sites and from 35 genes, in WT versus *Triaka* cIECs. (**C**) Transcript levels for the indicated isoforms were measured in WT and *Triaka* cIECs using qPCR and normalized to *Gapdh* expression (*n* = 6--11 mice per group). *Cd44v4-5: Cd44* variant 4--5. (**D**) Immunohistochemistry was performed on colonic tissue of indicated mice to detect total CD44 (CD44t) or CD44v4. Representative pictures and percentage of positive cells for the indicated staining intensities are shown (*n* = 5--6 mice per group, pooled from three independent experiments). Histograms represent the mean ± standard error of the mean. Statistics: (**C**) Student\'s *t* test; (**D**) Mann-Whitney test. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001.\
10.7554/eLife.28366.007Figure 2---source data 1.Altered ratios of transcript isoforms in *Triaka* epithelial cells.](elife-28366-fig2){#fig2}

*Esrp1^Triaka^* impairs the integrity of the intestinal barrier {#s2-3}
---------------------------------------------------------------

We next compared the gene expression profiling of *Triaka* versus WT cIECs to assess potential functional effects of *Esrp1^Triaka^*. Pathway analysis of the RNA sequencing data showed that several pathways involved in cell cycle and proliferation were affected in *Triaka* cIECs ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Yet, these transcriptional changes did not overtly alter intestinal histomorphology and epithelial proliferation, as crypt depth, number of goblet cells and Ki-67 expression were similar in *Triaka* versus WT mice ([Figure 3---figure supplement 2A--F](#fig3s2){ref-type="fig"}). Furthermore, *Triaka* and WT mice showed similar colon length at steady-state ([Figure 3---figure supplement 2G](#fig3s2){ref-type="fig"}). However, E-cadherin (CDH1) surface expression was reduced on *Triaka* cIECs ([Figure 3A and B](#fig3){ref-type="fig"}). Given the central role of E-cadherin for epithelial cell function, we hypothesized a possible defect in intestinal epithelial barrier integrity in *Triaka* mice. Indeed, ex vivo measurement of the intestinal electrical resistance indicated an increased ion permeability of *Triaka* versus WT colonic mucosa ([Figure 3C](#fig3){ref-type="fig"}), although there was no such difference in the small intestine ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}). This was accompanied by the presence of bacterial 16S rRNA in intestinal crypts and in the inner mucus layer of *Triaka* but not WT colons ([Figure 3D](#fig3){ref-type="fig"} and [Table 1](#table1){ref-type="table"}). As further indirect evidence of reduced barrier integrity, we also detected systemic anti-commensal IgG1 and IgG2b antibody reactivity towards autologous intestinal bacteria in most *Triaka* mice, but rarely in control animals ([Figure 3E](#fig3){ref-type="fig"} and [Table 1](#table1){ref-type="table"}). However, levels of fecal albumin and lipocalin-2 -- markers for intestinal lesions and inflammation -- were similar in fecal pellets of *Triaka* and WT mice ([Figure 3---figure supplement 3B and C](#fig3s3){ref-type="fig"}). Furthermore, there was no difference in the resorption of macromolecules between *Triaka* and WT mice (22 ± 1 versus 24 ± 3 µg/ml serum FITC-dextran-4000 levels, respectively, p=0.6).

![*Esrp1^Triaka^* decreases the barrier function of the intestine.\
(**A**) Representative flow cytometry plot of colonic single cells stained for EpCAM and CD45 (left panel). Representative histogram indicating surface E-cadherin expression on EpCAM^+^ epithelial cells (right panel). (**B**) Median fluorescence intensity (MFI) of E-cadherin expression on EpCAM^+^ cells from WT and *Triaka* mice. Data from one representative experiment of three are shown (*n* = 5 mice per group). (**C**) Intestinal barrier resistance in colonic tissue of WT and *Triaka* was measured using an Ussing chamber (*n* = 6 mice per group, pooled from two independent experiments). (**D**) Immunofluorescence for 16S rRNA (in red) was performed on colon tissue. Nuclei were visualized with DAPI. White arrows indicate presence of bacterial products in mucus and crypts of *Triaka* mice. Representative pictures are shown (*n* = 7--8 mice per group). Scale bars: overview: 200 µm; detail: 100 µm. (**E**) Commensal-specific IgG1 and IgG2b antibodies were assessed in the serum of WT and *Triaka* animals. Representative flow cytometry histograms are shown (*n* = 10 per group). Data are shown as mean ± standard error of the mean. Statistics: (**B**) and (**C**) Student\'s *t* test. \*\*p\<0.01; \*\*\*\*p\<0.0001.\
10.7554/eLife.28366.012Figure 3---source data 1.Gene expression and pathway analysis.](elife-28366-fig3){#fig3}

10.7554/eLife.28366.013

###### Bacterial translocation and serum anti-commensal antibodies.

                                               No. of WT mice   No. of *Triaka* mice   p-value
  -------------------------------------------- ---------------- ---------------------- ---------
  Penetration of bacteria in mucus or mucosa                                           
  16S rRNA                                     0/9              6/8                    0.0023
  Serum anti-commensal antibodies                                                      
  IgG1                                         1/10             7/10                   0.0198
  IgG2b                                        1/10             8/10                   0.0055

Statistics: Fisher\'s exact test was performed. This table relates to [Figure 3](#fig3){ref-type="fig"}.

In summary, these data suggest that reduced *Esrp1*-dependent mRNA splicing in *Triaka* animals results in decreased integrity of the colonic epithelial barrier and intestinal penetration of bacterial products. These epithelial defects are however not sufficient to induce intestinal immunopathology in naïve *Triaka* mice.

*Esrp1^Triaka^* modulates intestinal immunopathology {#s2-4}
----------------------------------------------------

Next, we addressed whether the *Esrp1^Triaka^*-dependent alterations observed at steady-state in *Triaka* mice may affect intestinal disease. Compared with WT controls, *Triaka* animals treated with dextran sodium sulfate (DSS) in drinking water for 7 days, a disease model of intestinal inflammation and damage, showed increased weight loss and pronounced shortening of the colon ([Figure 4A and B](#fig4){ref-type="fig"}). This was also reflected by higher disease scores, both clinically and histologically ([Figure 4---figure supplement 1A and B](#fig4s1){ref-type="fig"}). Notably, this phenotype was not due to an altered drinking behavior of *Triaka* animals ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). In addition, *Triaka* mice were also more susceptible to chronic DSS-induced colitis ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}).

![*Esrp1^Triaka^* modulates the course of experimental intestinal immunopathology.\
(**A**) WT (*n* = 7) and *Triaka* (*n* = 4) mice were challenged with 2% DSS in the drinking water for 7 days. Weight loss was measured daily (left panel). One representative out of four different experiments is shown. Representative H&E slides from colonic sections illustrate the degree of pathology in the different groups 7 days after the start of DSS treatment (right panel). Scale bars: 200 µm. (**B**) Colon length was measured in DSS-treated mice (*n* = 7--12 mice per group). (**C**) A miniature forceps was used to induce injuries in the colonic mucosa of the indicated groups of mice. Wound-healing was monitored by colonoscopy. Representative pictures (left panel) and quantification of wound-healing over time (right panel) are shown. Right panel represents pooled data from four independent experiments (*n* = total of 17 wounds from 8 to 9 mice, per group). (**D**) WT and *Triaka* mice were treated with AOM/DSS and sacrificed. Number of tumors, (**E**) tumor size and (**F**) the highest tumor grade per mouse are shown, assessed 70 days after the initial AOM injection. For (**D**), (**E**) and (**F**), one representative experiment of two is shown (*n* = 8--9 mice per group). (**G**) WT and *Triaka* mice were treated with 2% DSS in the drinking water for 3 days and Ki-67 staining was performed. Representative pictures are shown and (**H**) Ki-67-positive cells were quantified (*n* = 9--10 mice per group). Statistics: (**A**) and (**C**) Two-way ANOVA with Bonferroni post-test, (**B**) and (**H**) Student\'s *t* test, (**D**) Mann-Whitney test and (**E**) Student's *t* test with Welch's correction. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001.](elife-28366-fig4){#fig4}

To assess a possible functional consequence of the differential expression of proliferation-associated genes in *Triaka* versus WT cIECs, we applied an in vivo wound-healing model and followed the repair of experimentally-induced intestinal lesions in the two groups of mice. In these settings, we observed diminished wound-healing in *Triaka* compared with WT mice ([Figure 4C](#fig4){ref-type="fig"}). In contrast to what we observed at steady-state, these data imply that *Esrp1^Triaka^* impairs the proliferative or regenerative capacity of cIECs during intestinal pathology.

Next, we tested whether the increased susceptibility to DSS-colitis and the lower repair ability of *Triaka* mice may influence cell proliferation and pathogenesis in a CRC model. We found that in azoxymethane (AOM) and DSS-treated *Triaka* mice, colorectal tumors were reduced in number and size compared with WT controls, thus providing additional evidence for a defective proliferation of *Triaka* IECs ([Figure 4D and E](#fig4){ref-type="fig"}). The tumor grade was not different between the two groups ([Figure 4F](#fig4){ref-type="fig"}). However, molecular analysis revealed more pronounced upregulation of matrix metalloproteinase-3, granulocyte-colony stimulating factor, transforming growth factor β1 and interleukin-1α in *Triaka* versus WT tumors ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). These proteins are all established drivers of CRC progression, EMT and metastasis, thus indicating a more aggressive phenotype of *Triaka* tumors ([@bib37]; [@bib45]; [@bib44]; [@bib6]; [@bib42]). These features of *Esrp1^Triaka^* CRC lesions likely resulted from a partial EMT signature expressed by *Triaka* cIECs, prior to transformation ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}).

To address the hypothesis that the above-observed phenotypes were indeed due to impaired cIECs proliferation in *Triaka* mice, we last analyzed intestinal Ki-67 expression in the colonic mucosa, after a 3 day treatment with DSS. Under these conditions of mild intestinal inflammation, which are not sufficient to induce epithelial erosions, *Triaka* cIECs showed reduced Ki-67 expression compared with WT cIECs ([Figure 4G and H](#fig4){ref-type="fig"}).

Taken together, these results indicate that altered *Esrp1*-regulated mRNA splicing deregulates cIEC function and affects the development of intestinal disease in *Triaka* mice, through a mechanism reducing IEC proliferation.

*Esrp1^Triaka^* regulates the Wnt pathway via Gpr137 isoforms {#s2-5}
-------------------------------------------------------------

We next investigated the molecular mechanisms downstream of *Esrp1^Triaka^* that lead to diminished proliferation of *Triaka* IECs. Among the 35 genes showing splicing isoforms with different relative frequency in *Triaka* versus WT cIECs, we chose genes for which only two isoforms were differently expressed. Of those, *Gpr137* emerged as a prominent candidate since it is involved in IEC proliferation ([@bib73]), although the mode of action of this orphan G protein-coupled receptor (GPCR) or of its isoforms is unknown. Thus, the two *Gpr137* splicing isoforms with different relative frequency in *Triaka* versus WT cIECs, *Gpr137_ENSMUST00000166115* and *Gpr137*\_*ENSMUST00000099776* (referred hereafter as *Gpr137_Long* and *Gpr137_Short*, respectively), were selected for further functional studies. By using our in vitro reporter system, we could validate that *Gpr137* is a splicing target of ESRP1 ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Our RNA sequencing analysis indicated that *Gpr137_Long* is preferentially expressed in *Triaka* cIECs, whereas *Gpr137_Short* is predominant in WT cIECs. To address a potentially distinct role of *Gpr137_Long* versus *Gpr137_Short* in cIECs, CMT-93 cells were transduced with lentiviral vectors encoding these two *Gpr137* isoforms. We found a decreased cell proliferation and diminished epithelial monolayer tightness, as indicated by lower electrical resistance, in *Gpr137_Long-* versus *Gpr137_Short*-expressing cells. Importantly, in this particular assay the barrier function appeared to be distinct from the IEC proliferation. Indeed, although control vector-transduced cells proliferated less than cells transduced with vectors encoding *Gpr137* isoforms, they formed a tighter barrier ([Figure 5A and B](#fig5){ref-type="fig"}, [Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}). These effects of the two *Gpr137* isoforms on IEC proliferation and barrier integrity were independent of their relative expression levels and of possible cytotoxic effects ([Figure 5---figure supplement 2B and C](#fig5s2){ref-type="fig"}). Transduction with *Gpr137* isoforms also distinctively enhanced the proliferation of murine MC-38 and human Caco-2 IEC lines, thus validating our findings in CMT-93 cells ([Figure 5---figure supplement 2D and E](#fig5s2){ref-type="fig"}).

![GPR137 isoforms differentially activate Wnt/β-catenin signaling to modulate epithelial cell function.\
(**A**) CMT-93 IECs were transduced with vectors encoding the indicated *Gpr137* isoforms or a control vector (CTRL) and live cells were counted daily by microscopy. (**B**) Alternatively, monolayer resistance was assessed using a cellZscope device. (**C**) Flow cytometry analysis was performed to assess the activity of selected signaling pathways in *Gpr137* isoform-transduced CMT-93 cells. Median fluorescence intensity (MFI) of the indicated proteins (left panel) and representative histogram indicating the level of active β-catenin (right panel) are shown. (**D**) A WST-1 assay was used to assess the relative proliferation of *Gpr137* isoform-transduced CMT-93 cells in the presence or absence of the Wnt/β-catenin signaling inhibitor XAV-939. Proliferation was normalized to control vector-transduced cells. (**E**) Expression levels of active β-catenin in primary cIECs of WT and *Triaka* mice (*n* = 7--8 mice per group) were measured by flow cytometry (left panel). A representative histogram is also shown (right panel). (**F**) Transcript levels of selected Wnt/β-catenin signaling target genes were measured in primary cIECs of WT and *Triaka* mice (*n* = 7--8 mice per group). Data shown: One representative experiment performed in (**A and D**) biological triplicates or (**B**) quadruplicates, and which was repeated four times (**A**) or twice (**B and D**). Pooled data from (**C**) three individual experiments performed in biological triplicates or (**E and F**) two individual experiments. Statistics: (**A**), (**B**) and (**D**) Two-way ANOVA with Bonferroni post-test. (**C**), (**E**) and (**F**) Student\'s *t* test. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001.](elife-28366-fig5){#fig5}

To dissect the differential effect of the two *Gpr137* isoforms on CMT-93 cells, we then investigated the activation of signaling pathways known to regulate epithelial cell proliferation or barrier function. Among the pathways examined, differences were only observed for Wnt/β-catenin signaling. Indeed, we found a one-third reduction in levels of active β-catenin protein in *Gpr137_Long-* versus *Gpr137_Short*-transduced cells ([Figure 5C](#fig5){ref-type="fig"}), which was validated in *Esrp1^Triaka^*- versus *Esrp1*^WT^*-*transduced cells ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Furthermore, pharmacological inhibition of Wnt/β-catenin signaling abrogated the proliferative advantage of *Gpr137_Short-* over *Gpr137_Long*-transduced cells ([Figure 5D](#fig5){ref-type="fig"}). This suggested that *Gpr137* isoforms modify epithelial function via regulation of Wnt/β-catenin signaling. In line with these in vitro data, we measured ca. 40% reduced levels of active β-catenin, as well as diminished expression of Wnt target genes ([@bib21]) in cIECs of *Triaka* compared with WT mice ([Figure 5E and F](#fig5){ref-type="fig"}). Collectively, these results show that distinct *Gpr137* isoforms can differently modulate the Wnt/β-catenin pathway and IEC function, which may partially underlie the intestinal phenotype of *Triaka* mice.

ESRP1 expression is reduced in the diseased human intestine {#s2-6}
-----------------------------------------------------------

To address the general relevance of the findings from our in vitro and in vivo studies, we next assessed *ESRP1* expression in intestinal biopsies from Crohn's disease (CD) patients, after normalization to an epithelial-specific marker. Compared with non-inflamed paired biopsies, *ESRP1* levels were downregulated in the inflamed biopsies from CD intestines ([Figure 6A](#fig6){ref-type="fig"}). This correlated with reduced nuclear ESRP1 expression in the inflamed CD intestine, as measured by high-throughput automated immunohistochemistry quantification ([Figure 6B](#fig6){ref-type="fig"}).

![Expression of ESRP1 and *ESRP1*-dependent *hGPR137* isoforms is down-regulated in the diseased intestine and predicts CRC patient survival.\
(**A**) *ESRP1* transcript levels were measured in inflamed versus matched, non-inflamed intestinal biopsies from Crohn's disease (CD) patients and normalized to *EPCAM* expression. Normalized *ESRP1* transcript levels in the non-inflamed biopsy were set to one for each patient and fold induction was calculated for the corresponding inflamed biopsy (*n* = 15 samples per group). Data represent means ± standard error of the mean. (**B**) Immunohistochemistry was performed on intestinal tissue of CD patients to detect nuclear ESRP1, which was measured using automated quantification and normalized. Representative pictures are shown from a patient during remission and active disease, respectively (*n* = 31, 32, 7 and 14 biopsies per indicated group of cases). Data represent means ± standard error of the mean. Scale bars: 50 µm. (**C**) Kaplan-Meier survival curves of CRC patients with high (*n* = 77) or low (*n* = 88) expression of ESRP1 in tumor tissues. Representative IHC showing ESRP1-high and -low intestinal tumors. Scale bars: 100 µm. (**D**) Correlation between *ESRP1* and *hGPR137*\_*Short* expression in normal tissue of the large intestine (*n* = 51). (**E**) *hGPR137*\_*Short* and *hGPR137_Long* isoform expression in tumor (*n* = 647) versus normal (*n* = 51) tissue of the large intestine. Data represent means ± standard error of the mean. (**F**) Kaplan-Meier survival curves of CRC patients with a high (*n* = 142) or low (*n* = 261) ratio of *hGPR137_Short* to *hGPR137_Long* transcripts in tumor tissues. Statistics: (**A**) Wilcoxon signed-rank test, (**B**) One-way ANOVA with Bonferroni post-test, (**C**) and (**F**) Log-rank test, (**D**) Spearman correlation, (**E**) Kruskal-Wallis with Dunn's post-test. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001.\
10.7554/eLife.28366.025Figure 6---source data 1.Association of (nuclear) ESRP1 expression with clinicopathological features in 185 CRC patients.\
10.7554/eLife.28366.026Figure 6---source data 2.Univariate and multivariate survival analysis in 185 CRC patients.\
10.7554/eLife.28366.027Figure 6---source data 3.Correlation of *hGPR137_Short* with Wnt target genes.](elife-28366-fig6){#fig6}

We also performed a tissue microarray (TMA) based analysis of matched intestinal tissues from a cohort of 185 CRC patients, which revealed a gradual decrease in nuclear expression of ESRP1 protein during cancer progression ([Table 2](#table2){ref-type="table"}). Furthermore, low nuclear ESRP1 expression was associated with reduced patient survival (p*=*0.0456), larger tumors (p*=*0.0034), lymphatic invasion (p*=*0.0466), advanced pT-stage (p*=*0.02) and presence of nodal metastasis (p*=*0.016) ([Figure 6C](#fig6){ref-type="fig"} and [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). ESRP1 expression was determined to be an independent prognostic factor, after adjusting for the confounding effects of pT, pN, pM, tumor budding, and lymphatic invasion ([Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). This indicates a possible tumor-suppressive role of ESRP1 in CRC. Finally, we analyzed in The Cancer Genome Atlas (TCGA) RNA sequencing data of intestinal tissue from CRC patients to evaluate the relative frequency of *GPR137* isoforms in the human intestine. We found a positive correlation between the expression of *ESRP1* and *GPR137_ENST00000539833* (referred hereafter as *hGPR137_Short*) in normal intestine tissue, which we further validated using independent samples ([Figure 6D](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Moreover, there was an association between *hGPR137_Short* expression and transcript levels of Wnt target genes, suggesting a similar signaling downstream of GPR137 in humans and mice ([Figure 6---source data 3](#fig6sdata3){ref-type="supplementary-material"}).

10.7554/eLife.28366.028

###### Gradual loss of nuclear ESRP1 expression is associated with CRC progression

  Tissue type             Number of cases   ESRP1 expression (%)   p-value   
  ----------------------- ----------------- ---------------------- --------- ----------
  Normal                  26                75                     75        \<0.0001
  Adenoma                 42                56.8                   60        
  Carcinoma               185               26.5                   15        
  Lymph node metastasis   68                9.1                    0         

Statistics: Kruskal-Wallis test was performed. This table relates to [Figure 6](#fig6){ref-type="fig"}.

In human CRC, the ratio between *hGPR137_Short* and *GPR137_ENST00000377702* (referred hereafter as *hGPR137_Long*) isoforms was altered compared with normal intestinal tissue ([Figure 6E](#fig6){ref-type="fig"}). Similarly, transcript levels of *Gpr137_Long* were increased in murine CRC tissue ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Importantly, a higher ratio of *hGPR137_Short* to *hGPR137_Long* transcripts predicted enhanced CRC patient survival, thereby indicating a protective role of the *ESRP1*-dependent *hGPR137_Short* isoform ([Figure 6F](#fig6){ref-type="fig"}). Indeed, higher expression levels of *hGPR137_Short* alone was also associated with better prognosis ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}).

These findings extend our in vivo data in *Esrp1^Triaka^* mice and substantiate their relevance for the human intestine. They also suggest an involvement of *hGPR137* isoforms in human CRC tumorigenesis and progression.

Collectively, our data in mice and humans indicate that downregulation or loss of ESRP1 function results in dysregulation of alternative mRNA splicing in IECs. This leads to impaired epithelial cell integrity and contributes to intestinal pathology, possibly via altered *Gpr137*/*GPR137* isoform ratios ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}).

Discussion {#s3}
==========

Here, we describe a mouse model with hypomorphic ESRP1 function that shows impaired intestinal epithelial barrier integrity. This was associated with changes in the relative frequency of distinct mRNA isoforms in IECs and accompanied by an altered epithelial phenotype, as indicated by diminished surface E-cadherin expression. Of the 35 genes with splicing isoforms present at different ratios in *Triaka* versus WT primary cIECs, we identified two isoforms of *Gpr137* that differently affected IEC function via modulation of the Wnt signaling pathway. In support of these data from mouse models demonstrating a role for *Esrp1* in intestinal integrity, ESRP1 was downregulated in colonic tissue from CRC patients. Furthermore, the ratio of specific *GPR137* isoforms varied in tumor versus normal intestinal human samples, and expression of a specific *ESRP1*-dependent *GPR137* isoform predicted CRC patient survival. Little is known about GPR137, an orphan GPCR whose knockdown leads to reduced proliferation of several cancer cell lines, including colon cancer cells ([@bib73]). In particular, the function of distinct *Gpr137/GPR137* isoforms in IECs has not been addressed so far. GPR137 is ubiquitously and abundantly expressed in mouse tissues and is most closely related to OR51E2/PSGR, a prostate-specific GPCR ([@bib63]; [@bib51]).

Interestingly, recent data suggest that GPR137 may be involved in EMT. Indeed, silencing of *GPR137* resulted in a downregulation of SNAI1/SNAIL and SNAI2/SLUG and a corresponding increase in E-cadherin expression in human prostate cancer cells ([@bib53]). *Gpr137_Short* and *hGPR137_Short* are predicted to encode a protein with five transmembrane domains, whereas the products of *Gpr137_Long* and *hGPR137_Long* have a seven-transmembrane-spanning motif. Human and mouse GPR137 proteins have a 78% identity, yet the respective short and long isoforms we report here do not directly match between the two species. The molecular mechanisms by which distinct *Gpr137/GPR137* isoforms differently regulate Wnt/β-catenin signaling or possibly determine CRC survival have yet to be investigated.

Our data indicate a reduction of active β-catenin levels in primary *Esrp1^Triaka^* IECs and a subsequent downregulation of the transcription of some -- but not all -- Wnt target genes. Active β-catenin was similarly decreased in CMT-93 cells transduced with an *Esrp1^Triaka^*- or a *Gpr137_Long*-expressing lentiviral vector, compared to controls. The Wnt/β-catenin pathway is central to maintain tissue renewal and stem cell activity in IECs as well as epithelial cell proliferation in intestinal crypts. Genetic ablation of β-catenin in adult mice leads to intestinal epithelial stem cell (IESC) differentiation, thereby resulting in impaired intestinal homeostasis and fatal loss of intestinal function ([@bib17]). Reduced Wnt/β-catenin signaling likely underlies the diminished healing capacity of *Triaka* IECs and their reduced proliferation after transformation in the AOM/DSS model. In contrast, the Wnt/β-catenin pathway is aberrantly activated in most CRC, often caused by *APC* loss-of-function ([@bib10]). Therefore, our study suggests a link between ESRP1 and Wnt/β-catenin signaling in the intestine.

Besides *Gpr137*, we also revealed other genes with altered splicing patterns in *Triaka* compared with WT cIECs, which likely also contribute to the intestinal phenotype in *Triaka* mice. Among those ESRP1 target genes, *Cd44* is probably the most studied for its intestinal function. CD44 and its isoforms negatively regulate IEC apoptosis ([@bib71]; [@bib34]) and participate in various cellular functions, such as proliferation, adhesion, and migration ([@bib49]). Furthermore, *CD44v4* and *CD44v6* isoforms are overexpressed in neoplastic IECs of patients with familial adenomatous polyposis ([@bib72]). The expression of *Cd44v4* and *Cd44v6* isoforms in murine IESCs positively correlates with expression of LGR5, a marker of adult IESCs, and CD44 variant isoforms promote CRC in *Apc*^Min/+^ mice ([@bib72]). Therefore, the decreased expression of CD44v4 protein in *Esrp1^Triaka^* IECs may likewise explain the reduced intestinal tumorigenesis observed in *Triaka* compared with WT mice.

Although our data indicate reduced splicing activity from the *Triaka* mutation, a possible neomorphic effect of ESRP1*^Triaka^* cannot be fully excluded, and further investigation using other genetic models is required to examine this aspect.

ESRP1 has also been reported to restrict pluripotency in embryonic stem cells ([@bib14]), and it may as well regulate the differentiation of adult stem cells, including IESCs. Similarly, ESRP1 downregulation promotes cancer cell stemness and metastasis ([@bib50]). Accordingly, frameshift mutations of *ESRP1* are found in 25% of microsatellite instability-positive CRC tumors ([@bib26]). Furthermore, our results from a CRC cohort show that ESRP1 protein is gradually downregulated during the adenoma to carcinoma sequence in intestinal tumors and that few cells express it in lymph node metastases. These findings strengthen previous data suggesting a tumor-suppressive role of *ESRP1* in CRC cells ([@bib36]). Remarkably, ESRP1 appears to be involved early during CRC tumorigenesis, since it is already downregulated in adenoma. Reduction of ESRP1 function in adenomatous lesions may compromise the intestinal barrier, thereby facilitating the penetration of bacterial products and promoting inflammation-mediated CRC development ([@bib19]).

Our data in mice suggest that while AOM/DSS-induced *Triaka* tumors are smaller, they show a more aggressive molecular signature. We do not have a definitive explanation for these seemingly opposing results. However, ESRP1 is a key regulator of EMT -- it maintains the epithelial phenotype of a cell -- and ESRP1 downregulation leads to a shift towards a mesenchymal phenotype. Indeed, we find higher transcript levels of the EMT-promoting transcription factors *Zeb1* and *Zeb2* in *Triaka* compared with WT cIECs. As EMT is associated with reduced proliferation as well as increased motility and invasiveness of malignant cells, this may account for the phenotype of *Triaka* tumors ([@bib27]; [@bib13]; [@bib24]).

Although we investigated ESRP1 expression and not *ESRP1* mutations in human CRC, our in vitro data indicate a direct correlation between *ESRP1* expression and splicing activity mediated by ESRP1. Therefore, we believe that *Triaka* mice, characterized by decreased ESRP1 activity, represent a valid model to address the contribution of *Esrp1*-dependent mRNA splicing to intestinal function.

In summary, our results demonstrate a role for *Esrp1* in intestinal homeostasis and disease in mice. Our findings also suggest that loss of *ESRP1* may contribute to CRC and IBD development in humans. Moreover, we identified *GPR137* as a novel splicing target of ESRP1 and found that distinct isoforms of GPR137 regulate intestinal homeostasis by modulating IEC function through the Wnt/β-catenin pathway. Additional studies investigating the role of *GPR137* and *ESRP1* in the intestinal epithelium are warranted to understand how distinct GPR137 isoforms impact on CRC patient survival and to reveal strategies to target the ESRP1-GPR137 axis.

Materials and methods {#s4}
=====================

Patient selection {#s4-1}
-----------------

A multi-punch TMA of matched tumor, adenoma and normal tissue from 220 CRC well-characterized patients surgically treated from 2004 to 2007 at the Aretaieion University Hospital, University of Athens, Greece was used to evaluate changes in ESRP1 expression during tumor progression and impact on clinicopathological features (see also [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). Additionally, RNA*later* (Thermo Fisher Scientific, Waltham, MA) -stored and formalin-fixed paraffin-embedded biopsies from IBD patients were obtained from the Swiss IBD Cohort (<http://www.ibdcohort.ch/>) and from the Institute of Pathology of the University of Bern (Switzerland), respectively. Alternatively, CRC tissues were provided by the Tissue Bank Bern. The use of patient data and samples was approved by the Ethics Committee at the University of Athens, Greece and the Cantonal Ethics Committee of Bern.

Evaluation of ESRP1 in CRC and IBD cases {#s4-2}
----------------------------------------

Nuclear ESRP1 expression in CRC tissue was detected by immunohistochemistry (IHC) and scored by a pathologist (V.H.K.). In detail, each spot was evaluated for the percentage of epithelial cells showing ESRP1 expression (0--100%). Additionally, the intensity of staining was evaluated on a four point scale (0‐3). Final scores were formed by multiplication of these two values (range 0--300) and evaluated in correlation with clinicopathological features and survival. For the Kaplan-Meier curves, Receiver Operating Characteristic curve analysis was performed to identify the optimal immunohistochemical cut-off score with lymph node metastasis as the endpoint. Based on this analysis, a cutoff value of 20% ESRP1 expression in tumors was chosen to separate ESRP1-high from -low tumors. Univariate and multivariate survival analyses were carried out using Cox proportional hazards regression. All significant variables in univariate analysis were entered into multivariate analysis. Hazard ratios and 95% CI were used to determine the effect size for the outcome overall survival.

Nuclear ESRP1 expression in intestinal epithelial cells (IECs) was quantified using Oncotopix Discovery (RRID:[SCR_015690](https://scicrunch.org/resolver/SCR_015690); Visiopharm, Hoersholm, Denmark) and applying a custom-made algorithm developed by the authors. In brief, inflammation grade was assessed for each biopsy on H&E-stained tissue sections by a board-certified pathologist (V.G.), in a single-blinded manner, and classified into no, mild, moderate and severe inflammation. Sequential sections were then stained for ESRP1 and analyzed.

The analysis algorithm was first designed to automatically distinguish IEC areas from stroma and background. Nuclear ESRP1 expression in IECs was then stratified into no, low, moderate and high expression and the area of these different intensity values was quantified for each biopsy. Thereafter, the area-corrected mean brown stain intensity value was calculated for each biopsy. Finally, intensity values were normalized to mildly inflamed biopsies on each slide to control for potential staining variability between slides.

Immunohistochemistry and immunofluorescence of human and mouse tissue {#s4-3}
---------------------------------------------------------------------

IHC was performed on sections (2.5 μm) of IBD biopsies and on the TMA using the BondMax system (Leica, Wetzlar, Germany) in Bond Epitope Retrieval Solution 2 (citrate, pH 9.0) for 60 min at 95°C. Tissues were then stained for ESRP1 (1:50, Thermo Fisher Scientific, Waltham, MA). The Bond Polymer Refine Detection kit (Leica) was used for the detection of ESRP1-positive cells.

For IHC on formalin-fixed paraffin-embedded murine colon tissue, a heat-induced epitope retrieval was first performed for 18 min in a steam cooker in 1 mM Tris/1 mM EDTA (pH 9.0). A primary antibody detecting total CD44 (1:100, rat anti-mouse, Becton Dickinson, Franklin Lakes, NJ), CD44v4-containing isoforms (1:100, rat anti-mouse, eBioscience, Santa Clara, CA) or Ki-67 (1:200, Dako, Santa Clara, CA) were then used. Specific binding of primary antibodies was visualized using a secondary antibody (1:200, goat anti-rat, Dako) followed by a tertiary antibody with linked horseradish peroxidase (HRP) as the enzyme (EnVision+, anti-goat, Dako), and 3,3\'-diaminobenzidine as the chromogen. Staining intensity of positive cells was quantified using an automated scanner and software (Aperio, Sausalito, CA).

Bacterial 16S rRNA was detected with the eubacterial probe EUB338 (5'-GCTGCCTCCCGTAGGAGT-3') ([@bib40]) labeled with Alexa647 (Eurofins). Sections were counterstained with DAPI (1:2000, BioLegend, San Diego, CA) and placed in mounting medium (Dako). Fluorescence signal was detected using an Olympus IX81 confocal microscope combined with a FluoView FV1000 device (Olympus, Tokyo, Japan).

Animals {#s4-4}
-------

All animal experiments were performed in accordance with institutional and federal regulations governing animal care and use and were approved by The Scripps Research Institute (TSRI) Institutional Animal Care and Use Committee (La Jolla, CA, USA) (IACUC protocols 07--0057 and 09--0079) and the Cantonal Veterinary Office of Bern (Switzerland) (protocols BE76-11 and BE130/14). Animal experiments were carried out in compliance with the ARRIVE reporting guidelines. All strains used were on a C57BL/6 background. C57BL/6J mice (RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)) were purchased from Jackson Laboratories and thereafter bred in-house. *Esrp1^Triaka^* mice (RRID:[MGI:5515349](https://scicrunch.org/resolver/MGI:5515349)) were generated at TSRI using *N*-ethyl-*N*-nitrosourea. For all experiments, non-randomized groups of 8--12 week old *Esrp1^Triaka/Triaka^* and C57BL/6J animals were either co-housed (for females) or soiled bedding was exchanged weekly (for males) 3--4 weeks prior to and during experiments.

Identification of the *Esrp1^Triaka^* allele {#s4-5}
--------------------------------------------

The *Esrp1^Triaka^* allele was generated using *N*-ethyl-*N*-nitrosourea, as previously described ([@bib22]). It was initially identified to have a defect in natural killer cell (NK) cytotoxicity as well as a hyperactivity and circling behavior. These phenotypes segregated in subsequent breeding and the name *Triaka* was retained for the neurobehavioral phenotype. Initial confinement of the mutation was made by outcrossing of *Esrp1^Triaka/Triaka^* mutation mice to C3H/HeN mice, followed by backcrossing of F1 hybrids to the *Esrp1^Triaka/Triaka^* stock. The mutation was mapped to proximal Chromosome 4, with a peak LOD of 2.71 at D4mit235. Fine mapping further defined a critical region from the centromere to 13.7 mega base pairs. Whole genome sequencing of a homozygous *Triaka* mouse using SOLiD^TM^ (Thermo Fisher Scientific, Waltham, MA) revealed an A to G transition at position 828 of *Esrp1*, for which 86.3%, 74.9%, and 62.3% of coding/splicing sequence was covered at least 1×, 2×, or 3×, respectively. Validation sequencing of the critical region covered all nucleotides for which discrepancies were observed and confirmed the *Esrp1^Triaka^* mutation, which is located in exon 4 of 16 total exons of *Esrp1.* The circling behavior, which is incompletely penetrant among homozygous *Triaka* mice, was investigated in correlation with an auditory or neurodevelopmental defect. However, *Triaka* mice displayed normal hearing in tests for auditory brain stem response and distortion product otoacoustic emissions. In addition, there were no obvious abnormalities on histological sections of the neocortex, cerebellum, kidney, liver, lung, heart, pancreas, thymus and spleen. Adult (8 to 12 week old) *Esrp1^Triaka^* were slightly leaner than WT mice (19 ± 1 g versus 21 ± 1 g for females and 22 ± 2 g versus 26 ± 2 g for males, respectively), likely due to the hyperactive behavior. *Esrp1^Triaka^* mice were later found to be susceptible to acute challenge with 2% dextran sodium sulfate (DSS). Increased susceptibility to DSS was also observed in homozygous versus WT mice on a mixed C57BL/6J-C57BL/10J background. The *Triaka* strain is further described at the Southwestern Medical Center Mutagenetix database (<http://mutagenetix.utsouthwestern.edu>) ([@bib32]).

Evaluation of colonic crypt depth and goblet cells numbers {#s4-6}
----------------------------------------------------------

Colonic crypt depth was assessed in longitudinally-sectioned crypts on H&E-stained sections. Slides were scanned and crypt depth was digitally measured in 20 crypts per mouse and averaged using the Pannoramic Viewer software (RRID:[SCR_014424](https://scicrunch.org/resolver/SCR_014424); 3DHISTECH Ltd., Budapest, Hungary). Colonic goblet cell numbers were assessed in longitudinally-sectioned crypts on PAS-stained sections using the Pannoramic Viewer software. The number of PAS-positive cells per crypt was averaged from 10 crypts per mouse.

Fecal albumin and lipocalin-2 measurement {#s4-7}
-----------------------------------------

Fecal pellets were collected, weighed and resuspended in PBS containing 1% FBS. A sandwich ELISA for fecal albumin and lipocalin-2 was performed on 96-flat bottom Nunc MaxiSorp plates (eBioscience). A purified anti-mouse albumin capture antibody (Bethyl Laboratories, Montgomery, TX) and a secondary HRP-conjugated anti-mouse albumin antibody (Bethyl Laboratories) were used for the capture and detection of fecal albumin. A Substrate Reagent Pack (R&D Systems, Minneapolis, MN) was used for the color reaction and 1 M sulfuric acid was added to stop color development. Colorimetric signals were measured on a SpectraMax M2e device (Bucher Biotec AG, Basel, Switzerland). Fecal lipocalin-2 was measured using the mouse Lipocalin-2/NGAL MAb ELISA kit (R&D systems), according to the manufacturer's instructions.

Isolation and RNA sequencing of colonic intestinal cells {#s4-8}
--------------------------------------------------------

Colonic tissues were harvested and thoroughly washed in ice-cold calcium- and magnesium-free Hank's Balanced Salt Solution (HBSS). Colons were cut into 0.5--1 cm small pieces and digested in pre-warmed calcium- and magnesium-free HBSS containing 25 mM HEPES (Sigma-Aldrich, St. Louis, MO), 2 mM DTT (Sigma-Aldrich) and 5 mM EDTA (Merck, Darmstadt, Germany) at 37°C for 20 min. Supernatants were filtered through 70 µm cell strainers (BD Biosciences, San Jose, CA). The purity of colonic IECs (cIECs) was assessed by flow cytometry and was generally ≥95% of cIECs (defined as EpCAM^+^, CD45^−^ cells) in *Esrp1^Triaka^* and WT mice. Frequencies of major immune cell populations among CD45^+^ cells were analyzed in IEC preparations using the markers CD3, CD19 and CD11b and were comparable in both groups of mice. Isolated cIECs were pelleted and suspended in TRI-reagent (Sigma-Aldrich). For RNA sequencing, mRNA was purified and RNA concentration and integrity were assessed using a Bioanalyzer 2100 (Agilent, Santa Clara, CA) prior to cDNA synthesis and library preparation (TruSeq Stranded mRNA Sample Preparation, Illumina, San Diego, CA). The libraries were sequenced on an Illumina HiSeq2500 sequencer by the Next Generation Sequencing Platform of the University of Bern.

Computational analysis of RNA sequencing data {#s4-9}
---------------------------------------------

Between 45.7 and 59.1 million read pairs were obtained per sample. The reads were mapped to the mouse reference genome (Ensembl m38, build 75) using TopHat v. 2.0.11 (RRID:[SCR_013035](https://scicrunch.org/resolver/SCR_013035)) ([@bib31]). We then used HTseq-count v. 0.6.1 (RRID:[SCR_011867](https://scicrunch.org/resolver/SCR_011867)) ([@bib1]) to count the number of reads per gene, and DESeq2 v. 1.4.5 (RRID:[SCR_015687](https://scicrunch.org/resolver/SCR_015687)) ([@bib38]) to test for differential expression between groups of samples. To investigate alternative pre-mRNA splicing, we identified transcripts and quantified their expression levels as described in detail elsewhere ([@bib57]). Specifically, TopHat v. 2.0.11 ([@bib31]) was used to map the reads to the iGenomes reference (Ensembl NCBIM37 available from Illumina) for which an annotation file with Cufflinks-specific attributes is available. For each sample taken separately, transcripts were assembled with Cufflinks (RRID:[SCR_014597](https://scicrunch.org/resolver/SCR_014597)) and then combined into a single assembly with Cuffmerge (RRID:[SCR_015688](https://scicrunch.org/resolver/SCR_015688)), resulting in approximately 145,000 transcripts. We tested for differential expression between *Esrp1^Triaka^* and WT mice using Cuffdiff (RRID:[SCR_001647](https://scicrunch.org/resolver/SCR_001647)) and visualized the results with CummeRbund (RRID:[SCR_014568](https://scicrunch.org/resolver/SCR_014568)). In particular, we identified genes where the relative frequency of the isoforms from a given transcription start site (TSS) differed between *Esrp1^Triaka^* and WT mice (false discovery rate (FDR)-adjusted p-value\<0.05), consistent with alternative pre-mRNA splicing.

Pathway analysis {#s4-10}
----------------

The outcome of the DESeq2 analysis was taken to perform gene set enrichment analysis (GSEA) using the SetRank method (RRID:[SCR_015689](https://scicrunch.org/resolver/SCR_015689)) ([@bib56]). This algorithm first calculates the p‐value of a gene set utilizing the ranking of its genes in the ordered list of p‐value as determined by DESeq2. Next, it discards gene sets that have been initially flagged as significant, if their significance is merely due to the overlap with another gene set. Gene sets were derived from the following databases: REACTOME (RRID:[SCR_003485](https://scicrunch.org/resolver/SCR_003485)) ([@bib11]), Gene Ontology (RRID:[SCR_006447](https://scicrunch.org/resolver/SCR_006447)) ([@bib2]), LIPID MAPS (RRID:[SCR_006579](https://scicrunch.org/resolver/SCR_006579)) ([@bib15]), PhosphoSitePlus (RRID:[SCR_001837](https://scicrunch.org/resolver/SCR_001837)) ([@bib23]), KEGG (RRID:[SCR_012773](https://scicrunch.org/resolver/SCR_012773)) ([@bib28]), BIOCYC (RRID:[SCR_002298](https://scicrunch.org/resolver/SCR_002298)) ([@bib29]), ITFP (RRID:[SCR_008119](https://scicrunch.org/resolver/SCR_008119)) ([@bib74]) and WikiPathways (RRID:[SCR_002134](https://scicrunch.org/resolver/SCR_002134)) ([@bib30]). Counts indicated in [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"} were normalized for differences in total sequencing depth using size factor normalization in DESeq2.

Measurement of intestinal barrier resistance {#s4-11}
--------------------------------------------

Intestinal barrier integrity was measured ex vivo using an Ussing chamber (Dipl.-Ing. K. Mussler, Scientific Instruments, Aachen, Germany), as previously described ([@bib9]). In brief, colon tissue was isolated from *Triaka* and WT mice, washed in ice-cold calcium- and magnesium-free HBSS and then mounted in a 37°C warm, oxygen saturated and HBSS-containing Ussing chamber. Electrical resistance was measured after 10 to 15 min of equilibration time.

Measurement of serum anti-commensal antibodies {#s4-12}
----------------------------------------------

To assess systemic antibodies against intestinal commensals, fecal pellets were collected and intestinal bacteria from pellets were cultured in brain-heart infusion medium for 24 hours. Autologous fecal bacterial antibody binding was measured by bacterial flow cytometry. Complement in the serum was heat-inactivated and serum was titrated on sodium azide-inactivated bacteria. Specific binding of IgG1 and IgG2b to bacteria was detected with fluorochrome-labeled antibodies against mouse IgG1 or IgG2b (BioLegend, San Diego, CA) on a FACSArray device (BD Biosciences).

Induction and assessment of colitis in mice {#s4-13}
-------------------------------------------

For the induction of acute colitis, animals were given 2% DSS (MP Biomedicals, Santa Ana, CA) in the drinking water for 7 days, followed by regular water. For chronic colitis, DSS was given in 3 cycles with 5 days of DSS followed by 7 days of regular water. Animal weight was measured throughout the procedure. Intestinal inflammation was assessed in a single blinded manner on H&E-stained tissue sections by a board-certified pathologist (V.G.), as previously described ([@bib4]). Clinical disease activity was quantified as follows: Weight loss, compared to initial weight (Score 0, \<1% weight loss; score 1, 1--5% weight loss; score 2, 5--15% weight loss; score 4, 15--20% or more weight loss); Stool consistency (Score 0, normal stool; score 2, loose stool; score 4, diarrhea); Intestinal bleeding (Score 0, negative; score 2, positive).

Colon wound-healing assay {#s4-14}
-------------------------

Animals were anesthetized with isoflurane prior and during the experimental procedure. A miniature flexible biopsy forceps was used to inflict 2--3 mucosal injuries per mouse. The procedure was visualized using a miniature rigid endoscope system (Karl Storz, Tuttlingen, Germany). Wound-healing was continuously monitored by colonoscopy 3, 4, 5, and 7 days after the biopsy. To quantify the surface area of the excised mucosa and its subsequent regeneration, lesions were photographed and wound areas were measured using Photoshop (RRID:[SCR_014199](https://scicrunch.org/resolver/SCR_014199); Adobe Systems, San Jose, CA) and normalized to the forceps diameter.

Induction and assessment of intestinal tumors in mice {#s4-15}
-----------------------------------------------------

The azoxymethane (AOM) (Sigma-Aldrich)/DSS model of CRC was used to induce tumors, as previously described ([@bib12]; [@bib43]). In short, mice were injected intraperitoneally (i.p.) with AOM (10 mg/kg of body weight). After 7 days, mice were given 1% DSS in the drinking water for 5 days, followed by 7 days of regular water. Thereafter, animals received a second injection of AOM, which was followed by two further cycles of DSS and regular water. Mice were sacrificed 70 days after the first injection of AOM. Tumors were counted macroscopically and measured with a caliper by two independent observers. Tumor size was measured as previously described ([@bib46]). A board-certified pathologist evaluated the tumor grade in a single blinded manner. Grade was scored as follows: Grade 0: no tumor, healthy intestinal epithelium; Grade 1: adenoma with mild dysplasia; Grade 2: adenoma with moderate dysplasia; Grade 3: adenoma with severe dysplasia; Grade 4: adenoma with high grade dysplasia and infiltration of the lamina propria (carcinoma in situ); Grade 5: invasive carcinoma.

Cytokine measurements {#s4-16}
---------------------

Tumors or adjacent tumor-free colonic tissue were suspended in RIPA buffer (Sigma-Aldrich, St. Louis, MO) and homogenized using a TissueLyzer II (Qiagen, Venlo, Netherlands). Samples were then centrifuged and the protein concentration in the supernatant was measured with a Bradford Protein Assay (Bio-Rad, Hercules, CA). Protein concentrations were adjusted to 1500 µg/ml for each sample. Cytokines were analyzed by Multiplexing LASER Bead Technology (Eve Technologies, Calgary, Canada).

Flow cytometry {#s4-17}
--------------

IECs or intraepithelial lymphocytes were filtered through a 70 µm cell strainer (BD Biosciences) to obtain a single-cell suspension. Live/dead cell discrimination was performed using DAPI (BioLegend). Intracellular staining was performed after fixation of cells with 4% paraformaldehyde for 5 min and permeabilization with a 90% methanol solution at 4°C for 30 min. Antibodies used for flow cytometry are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Quantitative PCR analysis {#s4-18}
-------------------------

RNA from isolated colonic IECs was extracted using TRI-reagent (Sigma-Aldrich). RNA was then reverse-transcribed into cDNA using an M-MLV Reverse Transcriptase (Promega, Fitchburg, WI). FastStart SYBR Green Master (Roche, Basel, Switzerland) and commercial primers specific for *Cd44t, Cd44v4/v5*, *Gapdh, Jun, Nedd9, Fgf18, ESRP1,* and *EPCAM* (Qiagen, Venlo, Netherlands), as well as self-designed primers for specific isoforms of *Uap1*, *Magi1*, and G*pr137* ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) were used for the qPCR reaction. Reactions were performed and analyzed on a StepOnePlus Real-Time PCR System (Life Technologies, Carlsbad, CA). Unless indicated, transcript levels were normalized to *Gapdh* expression. For tissue biopsies from Crohn's disease patients, *ESRP1* transcript levels were normalized to *GAPDH* and *EPCAM* expression.

Generation of exon trap vector and in vitro assessment of splicing activity {#s4-19}
---------------------------------------------------------------------------

To generate a system to assess splicing events in vitro, an EcoRV restriction site was introduced into a commercially-available exon trap vector (MoBiTec, Göttingen, Germany) using the following primers: Fwd: 5'-GAGGCCCGATATCTTCAGACC-3'; Rev: 5'-GGTCTGAAGATATCGGGCCT-3'. A Firefly luciferase gene (Promega) lacking the ATG start codon was then cloned into this EcoRV site. The variable exon 5 of *Cd44* along with parts of the flanking introns were amplified using the following primers; Fwd: 5'-CGCGGGCTCGAGCATTGCAACAGATATAGAGACAGAATC-3'; Rev: 5'-CGCGGGGCGGCCGCCCTCTTTCAGGCTCTGCAGA-3'. Similarly, a region of *Fgfr2* containing exon IIIb and IIIc, the intron in-between, as well as parts of the flanking introns were amplified using the following primers; Fwd: 5'- CGCGGGCTCGAGGTCTGTTCTAGCACTACGGGGAT-3'; Rev: 5'- CGCGGGGCGGCCGCGCAGTATGTACCTGGCGAAC-3'. For the cloning of the region of *Gpr137* containing exons 2 and 3, we performed a first amplification using the following primers; Fwd: 5\'-GTGATGGGGTATCTCTGCTCC-3\'; Rev: 5\'-CCTTGATGTAGCACCCTTGGG-3\'. This amplicon was then used to perform a nested PCR reaction using the following primers; Fwd: 5\'-CTCCCAGGTGGTGTTCAATAGGCC-3\'; Rev: 5\'-CCAAGGTAGAGCCACC AACC-3\'. 

Amplicons were then cloned into the multiple cloning site of the modified exon trap vector. To generate vectors encoding *Triaka* or WT *Esrp1*, cDNA of *Esrp1*^WT^ and *Esrp1^Triaka^* were amplified using the following primers: Fwd: 5'-CGCGGGGGATCCGCCACCATGACGGCGTCTCCGGATTA-3'; Rev: 5'-CCCGCGGTCGACCTTAAATACAAACCCATTCTTTGGG-3'. Amplicons were then cloned into a pBRIT-HA/FLAG vector (Addgene, Cambridge, MA). A third vector containing a Renilla luciferase gene was also used to control for variations in the transfection efficiency (Promega). HEK-293 cells (RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)) were transiently transfected by calcium phosphate co-precipitation with the modified exon trap vector containing the cloned *Cd44* or *Fgfr2* regions, the *Esrp1*^WT^- or the *Esrp1^Triaka^*-encoding vector, and the Renilla luciferase-encoding vector. Firefly and Renilla luciferase activities were measured 24 hours after transfection in an Infinite 200 PRO reader (Tecan, Männedorf, Switzerland), using the Dual-Luciferase Reporter Assay (Promega). All cell lines were routinely tested negative for mycoplasma contamination.

Quantification of cell proliferation and epithelial monolayer resistance {#s4-20}
------------------------------------------------------------------------

CMT-93 cells (RRID:[CVCL_1986](https://scicrunch.org/resolver/CVCL_1986)) were cultured as recommended by ATCC. Cell proliferation was either assessed by manual cell counting or using a WST-1 assay (Roche). In brief, 8 × 10^4^ cells were seeded into 6-well plates and cells were counted daily using a Neubauer chamber. Alternatively, 2--8 × 10^3^ cells were seeded into a 96-well plate and proliferation was measured using a WST-1 assay, according to the manufacturer's instructions.

To measure the trans-epithelial electrical resistance (TEER) of transduced CMT-93 cells, 4 × 10^4^ cells were seeded onto rat tail collagen (Sigma Aldrich) coated 24-well plate ThinCerts^TM^ inserts (Greiner Bio-One, Kremsmünster, Austria). These inserts were then placed into a cellZscope device (nanoAnalytics, Münster, Germany) and TEER was measured every hour for up to 72 hours.

Construction and evaluation of tissue microarrays (TMAs) {#s4-21}
--------------------------------------------------------

Patient information on gender, age at diagnosis, tumor diameter, tumor location, post-operative therapy and disease-specific survival time was extracted from clinical records. The UICC TNM Classification 7th edition was used to assess the T- (pT), N- (pN), and M-stage (pM), lymphatic invasion (L), venous invasion (V), perineural invasion (Pn), tumor grade (G), histological subtype as well as tumor growth pattern. For each case, two TMA spots (diameter 0.6 mm) each of tumor center and tumor front and one spot of normal mucosa were stained for ESRP1 by immunohistochemistry (IHC). We excluded 35 cases based on insufficient material remaining on the tissue block. Final number of patients with invasive CRC was 185. From these patients, additional TMAs containing matched samples of normal colonic mucosa (*n* = 26), adjacent adenomas (*n* = 42) and lymph node metastases (*n* = 68) were constructed. Patient characteristics are indicated in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}.

Lentiviral overexpression system {#s4-22}
--------------------------------

Lentiviruses encoding *Gpr137_Long* or *Gpr137_Short* were generated using HEK-293 cells as previously described ([@bib58]). In brief, HEK-293 cells were transfected with pMD2G, pMDLg/pRRE, pRSV-Rev and pLV (Cyagen Biosciences, Santa Clara, CA) encoding EGFP with either *Gpr137_Long*, *Gpr137_Short,* or a control sequence. HEK-293 cells were authenticated by short tandem repeat (STR) profiling and confirmed to be mycoplasma-negative monthly. Lentiviruses were then harvested to infect CMT-93 cells. Transduced CMT-93 cells were sort-purified based on EGFP expression and kept under selection pressure using 5 µg/ml Puromycin (Sigma-Aldrich). CMT-93 cells were originally purchased from the European Collection of Cell Cultures (ECACC no. 89111413) and confirmed to be mycoplasma-negative monthly.

A 4-hydroxytamoxifen inducible system previously described elsewhere ([@bib64]; [@bib67]) was modified to overexpress *Esrp1^Triaka^*, *Esrp1*^WT^ or EGFP. To this aim, we exchanged the *Hoxb8* cassette of the original vector with cDNA of *Esrp1^Triaka^* or *Esrp1*^WT^. CMT-93 cells were then co-transduced with lentiviral vectors containing these different inserts and a lentiviral vector encoding a 4-hydroxytamoxifen responsive element. Co-transduced cells were kept under selective pressure using 5 µg/ml Puromycin and 200 µg/ml Hygromycin-B (Sigma-Aldrich). Expression of *Esrp1^Triaka^*, *Esrp1*^WT^ or EGFP was induced with 100 nM 4-hydroxytamoxifen.

Data availability {#s4-23}
-----------------

RNA sequencing data form *Triaka* and WT IECs can be downloaded from the European Nucleotide Archive (ENA) (<http://www.ebi.ac.uk/ena/data/search?query=PRJEB14221>). All RNASeqV2 data for datasets COAD and READ ([@bib8]) where downloaded though the TCGA data portal (COAD: tumor: *n* = 480; normal tissue: *n* = 41. READ: tumor: *n* = 167; normal tissue: *n* = 10) (<https://tcga-data.nci.nih.gov/docs/publications/coadread_2012/>; RRID:[SCR_003193](https://scicrunch.org/resolver/SCR_003193)). From the RSEM results Tables, we extracted gene expression levels for *ESRP1*, for all eight reported *GPR137* isoforms, for Wnt target genes specific for CRC ([@bib21]), as well as survival data. All results are shown as transcripts per million obtained by multiplying the provided scaled estimates by 10^6^. The sequences of all *GPR137* isoforms were obtained from the FASTA file in the GAF bundle (hg19, June 2011).

For analysis of the survival data from the TCGA dataset, the X-tile software (RRID:[SCR_005602](https://scicrunch.org/resolver/SCR_005602)) ([@bib7]) was used to separate *GPR137_Short*-high from -low tumors. CRC Patients without survival data or with undetectable gene expression were excluded from the survival analysis.

Statistical analysis {#s4-24}
--------------------

Sample size for in vivo studies was estimated by power analysis and adjusted for β = 0.1, with the assumption that differences between the groups were 1.5--2 fold. Statistical tests are two-sided and indicated in the figure legends. All statistical tests were performed with GraphPad Prism v.5.04 for Windows (RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798); GraphPad Software, La Jolla, CA). Statistical tests were chosen based on the variation in each data group and on whether multiple comparisons were made. Groups with similar variance were compared using parametric tests, and groups with significantly different variations were analyzed using non-parametric tests. No mouse was excluded from the analysis. Only statistically significant differences are indicated in the figures. For all statistical analyses: \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001.
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Major datasets {#s7}
--------------

The following dataset was generated:

Mager LKoelzer VStuber RThoo LKeller IKoeck ILangenegger MSimillion CPfister SPFaderl MGenitsch VTcymbarevich IJuillerat PLi XXia YKaramitopoulou ELyck RZlobec IHapfelmeier SBruggmann RMcCoy KDMacpherson AJMüller CBeutler BKrebs P2017Assessment of transcript isoforms in Esrp1Triaka versus wild-type primary colonic epithelial cells<https://www.ebi.ac.uk/ena/data/view/PRJEB14221>Publicly available at the EMDataBank (accession no.PRJEB14221)

The following previously published datasets were used:

The Cancer Genome Atlas Network2012TCGA-COAD<https://portal.gdc.cancer.gov/projects/TCGA-COAD>Publicly available from the NCI GDC Data Portal (https://portal.gdc.cancer.gov)

The Cancer Genome Atlas Network2012TCGA-READ<https://portal.gdc.cancer.gov/projects/TCGA-READ>Publicly available from the NCI GDC Data Portal (https://portal.gdc.cancer.gov)
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Decision letter
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Florian

Reviewing Editor

Germany

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The ESRP1-GPR137 axis contributes to intestinal pathogenesis\" for consideration by *eLife*. Your article has been favorably evaluated by Wendy Garrett (Senior Editor) and three reviewers, one of whom served as Guest Reviewing Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. We hope you will be able to submit the revised version within two months.

Summary:

In order to examine the role of ESRP1 in the intestinal epithelium, the manuscript takes advantage of the *Esrp1^Triaka^* model that exhibits a point mutation in *Esrp1* resulting in a single amino acid substitution (M161V) since conventional KO mice as well as mice with a conditional deletion of ESRP1 in the skin epithelium are not viable. Differential splicing of *Gpr137* in *Triaka* mice is identified here as one of the key downstream events and is a mechanism of how *Esrp1* controls intestinal homeostasis. Interestingly, the Triaka mutation sensitizes mice to chemical colitis (DSS), presumably triggered by an increased intestinal permeability and decreased Wnt signaling. However, due to the defects in intestinal regeneration the incidence of colitis-associated tumors in the AOM/DSS model is reduced yet the tumors seem more aggressive. This is an interesting phenomenon because often-increased colitis causes more (not less) cancer. A correlation between *Esrp1* and *Gpr137* are confirmed in IBD and CRC patients providing evidence for *Esrp1* loss being correlated with poor prognosis in CRC.

Essential revisions:

1\) A central point of the manuscript is the effect on intestinal barrier integrity upon decreased ESRP1 expression. Here the authors should extend their attempts to explain the underlying mechanism and should perform a targeted and more comprehensive analysis of tight junction proteins. Moreover, increased bacterial translocation and anti-commensal antibody response, but normal fecal albumin, lipocalin and FITC-dextran permeability may indicate specific defects in mucus.

Does *Esrp-1* regulate splicing in *Muc2* or any enzymes known for modifications/glycosylation of *Muc2*?

2\) The authors suggest that the ESRP1-mutated tumors are more aggressive and show signs of EMT. This appears to only be supported by an expression analysis of E-cadherin. The existence of EMT features should be supported by the inclusion of additional markers.

3\) The human data, which enriches the vast amount of granular experiments performed in order to study the *Esrp1^Triaka^* model, highlight that *Esrp1* deserves attention from the community and certainly warrants further studies. For the human data on survival tables, please highlight the patient characteristics and the exclusion of differences that might explain survival benefits.

Minor points:

1\) While the authors clearly show altered expression of two known targets of Esrp1 and decide to study hypofunctional *Esrp1* in intestinal epithelial cells, the exact consequence of the Esrp1-M161V substitution and its effects on Esrp1 function remains difficult to determine. Specifically, while both *Cd44v5* and *Fgfr2-*IIIb expression serve as proof-of-principle and are diminished in *Esrp1^Triaka^* mice, the degree to which they are diminished differs vastly. Is it possible that reduced function of Esrp1 (albeit to different degrees for each individual target) or potentially additional \'off\'-target effects (modifying some of the 35 identified Ersp1-targets) explain parts of the phenotype. Please expand discussion on these topics.

*Reviewer \#1:*

The manuscript by Mager and colleagues addresses the function of ESRP1 in intestinal epithelial cells. Using various in vivo and ex vivo assays the authors demonstrate a role for ESRP1 in epithelial barrier integrity and intestinal cell proliferation leading to increased susceptibility to DSS induced colitis and reduction of intestinal tumors when ESRP1 is absent. The authors claim that differential expression of *Gp137* isoforms contributes to these phenotypes. This is an interesting study that contains a large amount of human data and several experimental mouse models based on the development of a novel knockout mouse. The study is overall well performed and the data is well presented. While the manuscript is a little premature in terms of definite mechanistic insight into the exact molecular mechanism, the authors provide a very interesting data that will be the basis for further experiments. The greatest concern I have, however, is that most of the data is very correlative.

The following points should be addressed to improve this study:

1\) Is there any difference in the expression of components of the tight junctions? This would support the authors' claim about a barrier defect.

2\) Is there any clear evidence for the existence of EMT apart from changes in E-cadherin?

*Reviewer \#2:*

Mager et al. address the role of *Esrp1* (splicing regulator) -- *Gpr137* (orphan receptor) in regulation of intestinal homeostasis, colitis and cancer.

This study uses novel mouse line generated through ENU mutagenesis, a hypomorph allele of splicing regulator *Esrp1* -- called *Triaka* mice. As opposed to complete whole body or cell type specific knockout, *Triaka* mice are relatively normal, which allows the subsequent analysis in health and disease.

Differential splicing of *Gpr137* in *Triaka* mice is identified here as one of the key downstream events and is a mechanism of how *Esrp1* controls intestinal homeostasis. *Triaka* mutation predisposes mice to chemical colitis (DSS), may be because of increased permeability and decreased Wnt signaling, but due to the defects in intestinal regeneration reduces AOM+DSS colitis associated cancer. This is an interesting phenomenon because often-increased colitis causes more (not less) cancer. IBD and cancer related-phenomenon, as well as correlation between *Esrp1* and *Gpr137* are confirmed in IBD and CRC patients. *Gpr137*, whose alternative splicing is regulated by *Esrp1*, is identified as a negative regulator of Wnt/b-catenin signaling, linking *Triaka* mutation with defective proliferation of epithelial cells. Overall, this manuscript is very solid on its novelty of the mouse models and characterization of molecular events associated with *Esrp1* regulated splicing and on phenotypical characterization of intestinal pathology in *Triaka* mice. It is a little bit thin on mechanistic details further connecting *Esrp1- Grp13*7- b-catenin to intestinal phenotypes, but I think the authors have provided a new mouse model, very well characterized in vivo phenotype, solid in vitro data and human data. It really looks like this manuscript can open up the field to more questions and studies, but this story presented here is already solid enough by itself. Minor criticism is listed below:

1\) Increased bacterial translocation and anti-commensal antibody response, but normal fecal albumin, lipocalin and FITC-dextrane permeability may indicate specific defects in mucus. Does Esrp-1 regulate splicing in Muc2 or any enzymes known for modifications/glycosylation of Muc2?

*Reviewer \#3:*

In the current manuscript Mager et al. study the role of ESRP1 in the intestinal epithelium. Since conventional KO mice as well as mice with a conditional deletion of ESRP1 in the skin epithelium proved to be neonatal lethal the authors utilize the *Esrp1^Triaka^* model that exhibits a point mutation in *Esrp1* resulting in a single amino acid substitution (M161V). In this model the authors find a reduced but not abolished alternative splicing activity for two known targets of *Esrp1 (Cd44v5* and *Fgfr2*-IIIb). The authors subsequently identify 35 target genes in *Esrp1^Triaka^* mice that show an altered frequency of splicing isoforms compared to Wt mice. The authors then show an impaired barrier function along with increased susceptibility to DSS-colitis in *Esrp1^Triaka^* mice and smaller/less frequent but more aggressive tumors in the AOM-DSS model. The authors then focus on altered expression of *Gpr137* isoforms resulting in differential Wnt pathway activation as a mechanistic basis. Moreover, the authors are able to support their studies with human data showing less *Esrp1* expression in inflamed IBD biopsies, as well as providing evidence for *Esrp1* loss being correlated with poor prognosis in CRC. The authors are further able to link in human CRC differential *Gpr137* isoform expression with altered survival.

The major limitation of this study lies in the utilization of the *Esrp1^Triaka^* model itself. While clearly the authors show altered expression of two known targets of *Esrp1* and conclude therefore to study hypofunctional *Esrp1* in intestinal epithelial cells, the exact consequence of the *Esrp1*-M161V substitution and therefore on *Esrp1* function remains difficult to determine. Therefore, the relevance of studying this specific point mutation in the absence of an association with human disease is at least somewhat limited. Specifically, while both *Cd44v5* and *Fgfr2*-IIIb expression that serve as proof of principle are diminished in *Esrp1^Triaka^* mice the degree to which they are diminished differs vastly. Therefore it cannot be fully addressed if indeed reduced function of *Esrp1* (albeit to different degrees for each individual target) or additional off-target effects (artificially modifying some of the 35 identified *Ersp1*-targets) explain parts of the phenotype. Have the authors considered at all to study *Esrp1* heterozygous KO mice (*Esrp1*+/-) or mice exhibiting a heterozygous conditional deletion within the intestinal epithelium? Alternatively, a conditional deletion of both alleles at a later time point e.g. 6 weeks of age utilizing e.g. Vcre-ERT2 mice might provide additional insight.

Despite this limitation one has to congratulate the authors for this current work and the insight it generates for a potential role of *Ersp1* in the intestinal epithelium and more specifically in CRC. The experiments are thoroughly performed and conclusions supported by multiple lines of evidence. The human data, additionally to the vast amount of granular experiments performed in order to study the *Esrp1^Triaka^* model, highlight that *Esrp1* deserves attention from the community and certainly warrants further studies. For the human data on survival tables highlighting the patient characteristics and the exclusion of differences that might per se explain survival benefits still need to be added. This reviewer enjoyed very much reading the manuscript.

10.7554/eLife.28366.045

Author response

> Essential revisions:
>
> 1\) A central point of the manuscript is the effect on intestinal barrier integrity upon decreased ESRP1 expression. Here the authors should extend their attempts to explain the underlying mechanism and should perform a targeted and more comprehensive analysis of tight junction proteins. Moreover, increased bacterial translocation and anti-commensal antibody response, but normal fecal albumin, lipocalin and FITC-dextran permeability may indicate specific defects in mucus.

To better assess barrier integrity in *Triaka* mice, we consulted the literature to compile an extensive list of (intestinal) genes belonging to the occludine-, claudine-, tight junction protein (TJP)- and junctional adhesion molecule (JAM) family (1, 2). We then analyzed our RNA-sequencing data to assess the transcript levels of these 21 selected genes.

We found that E-cadherin (*Cdh1*) transcripts were most abundant, showing in wild-type (WT) colonic intestinal epithelial cells (cIECs) a \~2 fold higher expression level than messages from the next coming gene, *Cldn7*. Yet, *Cdh1* transcript levels were decreased in *Triaka* compared to WT cIECs ([Author response image 1A](#respfig1){ref-type="fig"}). These findings on different *Cdh1* expression could be independently validated by real time quantitative PCR analysis from additional *Triaka* and WT cIECs ([Author response image 1B](#respfig1){ref-type="fig"}). They also further corroborate our data indicating reduced E-cadherin protein expression on *Triaka* cIECs ([Figure 3A and B](#fig3){ref-type="fig"}).

E-cadherin is an epithelial adherens junction protein with central function for the formation of adherens junctions and desmosomes. Consequently, constitutive *Cdh1*-deficiency in IECs is neonatal lethal (3), while E-cadherin loss in IECs of adult mice leads to intestinal disease due to loss of intestinal epithelial integrity (4). Furthermore, *Cdh1*-deficient IECs showed compromised barrier function (3). Taken together, it is thus conceivable that the reduction of E-cadherin expression on *Triaka* IECs accounts for the reduced intestinal tightness in *Esrp1*-mutant mice. As cIECs have been described to be more dependent on E-cadherin expression for their integrity than IECs from the small intestine (4), this may possibly explain why in *Triaka* mice the large intestine -- but not the small intestine -- shows reduced intestinal electrical resistance ex vivo (see main manuscript).

Relatively to E-cadherin, the other (tight) junction proteins were less expressed in mouse IECs. Surprisingly, *Cldn8* and *Tjp2* were upregulated in *Triaka* versus WT cIECs, with 1.23 fold and 1.96 fold increase, respectively ([Author response image 1A](#respfig1){ref-type="fig"}). This may represent compensatory changes subsequent to E-cadherin down-modulation, as previously reported for other cell-cell adhesion genes (5).

In summary, these results suggest that downregulation of E-cadherin is the most relevant alteration in junction protein expression in *Triaka* versus WT cIECs, which likely contributes to impaired barrier integrity in *Esrp1^Triaka^* mutant mice.

![Expression analysis of selected genes with known function for intestinal barrier integrity.\
(**A**) RNA sequencing was performed on colonic intestinal epithelial cells (cIECs) from *Triaka* and WT mice to assess expression of the indicated genes (*n* = 4 mice per group). (**B**) Quantitative PCR was performed to determine *Cdh1* transcript levels in *Triaka* versus WT cIECs, after normalization to *Gapdh* expression (*n* = 13-14 mice per group). Statistics: (**A**) Benjamini-Hochberg adjusted p-values from test for differential gene expression. (**B**) Student's *t* test. \*\*, *P* \< 0.01; \*\*\*\*, *P* \< 0.0001.](elife-28366-resp-fig1){#respfig1}

> Does Esrp-1 regulate splicing in Muc2 or any enzymes known for modifications/glycosylation of Muc2?

Muc2 and MUC2 modifying enzymes -- ESRP1-dependent mRNA splicing:

To address this point, we have specifically compared the splicing pattern of Mucin 2 (*Muc2*) isoforms in *Triaka* versus WT cIECs. In agreement with the data represented in [Figure 2B](#fig2){ref-type="fig"}, there was no difference in the relative expression of *Muc2* isoforms. This suggests that ESRP1 does not regulate the splicing of *Muc2* transcripts.

We next investigated whether ESRP1 may possibly affect the splicing of transcripts of genes involved in the post-translational modification of MUC2. MUC2 protein becomes heavily O-glycosylated (6, 7), a process that is controlled by different glycosyltransferases (8). The initiation of O-glycosylation is performed by peptidyl-GalNAc transferases which add GalNAc to cell surface and secreted proteins being processed in the Golgi apparatus (7).

Thus, we compiled a list of all peptidyl-GalNAc transferases (a total of 19 in mice) as well as other glycosyltransferases previously identified in mouse IECs (9, 10); this list included *Galnt1, Galnt2, Galnt3, Galnt4, Galnt5, Galnt6, Galnt7, Galnt9, Galnt10, Galnt11, Galnt12, Galnt13, Galnt14, Galnt15, Galnt16, Galnt17, Galnt18, Galnt19, Galnt20, St6galnac6, St6galnac2, St6gal1, St3gal6, St3gal4, Gal3st2, Fut2, Chst4, B4galnt2, B4galnt1, B3gnt7, B3gnt3, B3galt5, B4galt4, B4galt1, Gcnt3, C1galt1c1 and C1galt1*. Analysis of our RNA sequencing data for splicing events in transcripts of these genes -- which was performed for those transcripts expressed in sufficient levels in murine cIECs for this kind of analysis -- did not uncover potential targets of ESRP1-dependent splicing in our model. This is also indicated in [Figure 2B](#fig2){ref-type="fig"}.

MUC2 function also depends on proteolytic cleavage i.e. for the expansion of the mucus layer at the border of the inner to outer mucus layer of the colon (11). MUC2 is cleaved either through endogenous (12, 13) or bacteria-derived enzymes (14). Since the precise identities of these endogenous enzymes are currently unknown (12), we assessed whether ESRP1-dependent splicing may target transcripts from genes encoding proteolytic enzymes present in the inner and other mucus layer (12). Of these analyzed genes (*Apeh, Blmh, Casp1, Cndp2, Dnpep, Ggh, Klk, Lap3, Mep1b, Npepps, Pa2g4, Park7, Pgcp, Prep, Psma2, Psma4, Psma5, Psma6, Psma7, Psmb1, Psmb2, Psmb3, Psmb4, Psmb5, Psmb6, Rnpep, Thop1, Usp5*), none were found to overlap with identified ESRP1 targets in our dataset (see also [Figure 2B](#fig2){ref-type="fig"}).

Lastly, we also assessed datasets from previous studies analyzing ESRP1-dependent splicing events in skin, urethral or pituitary cells (15-17). Systematic search of all the above-mentioned genes did not reveal isoforms of *Muc2* or of genes encoding enzymes involved in MUC2 post-translational modifications that are spliced in an ESRP1-dependent manner. However, it has to be mentioned that some of the above-listed genes are preferentially expressed in the intestine and may therefore not have been detected in these different RNA sequencing studies.

In summary, these data suggest that *Muc2* or MUC2-modifying genes are not directly affected by ESRP1-mediated mRNA splicing.

Muc2 and MUC2 modifying enzymes -- transcript levels:

We next surmised that *Esrp1^Triaka^* might have indirectly altered the relative expression of these different genes involved in post-translational modification of MUC2 (all listed above). We thus analyzed our RNA sequencing data to assess whether transcript levels of these genes were differently expressed in *Triaka* versus WT cIECs. Of the 65 analyzed genes, only few displayed significant changes, with minor changes in expression levels, i.e. \~30% up- or downregulation in *Triaka* versus WT cIECs (upregulated genes: *Galnt3*, 1.27 fold, *Lap3*, 1.3 fold change; downregulated genes: *St6galnac6*, 0.73 fold; *St3gal6*, 0.79 fold; *St3gal4*, 0.67 fold and *B3galt5*, 0.73 fold change; [Author response image 2](#respfig2){ref-type="fig"}).

Finally, while gene ontology analysis disclosed that the expression of genes involved in cell cycle and proliferation was affected in *Triaka* compared to WT cIECs ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}, main manuscript), no alterations were detected in pathways or gene sets involved in barrier function or mucus production/modification ([Author response table 1](#resptable1){ref-type="table"} below).

As these changes in expression are rather marginal and since gene ontology analysis did not identify alterations in barrier function or mucus production/modification in *Triaka* cIECs, we conclude that the differences in transcript levels of *Galnt3, Lap3, St6galnac6, St3gal6, St3gal4, B3galt5* are likely not biologically relevant.

![Expression analysis of selected genes with known function for post-translational modification of intestinal mucus.\
RNA sequencing was performed on colonic intestinal epithelial cells (cIECs) from *Triaka* and WT mice (*n* = 4 mice per group) to assess expression of the indicated genes involved in (**A**) glycosylation or (**B**) proteolytic cleavage of MUC2. Statistics: Benjamini-Hochberg adjusted p-values from test for differential gene expression.](elife-28366-resp-fig2){#respfig2}

10.7554/eLife.28366.035

###### Unaltered barrier function or mucus production/modification pathways in *Triaka* cIECs.

  SetID        Database   Description                                             Change *Triaka* vs. WT
  ------------ ---------- ------------------------------------------------------- ------------------------
  GO:0070254   GOBP       mucus secretion                                         Not significant
  GO:0070255   GOBP       regulation of mucus secretion                           Not significant
  GO:0070256   GOBP       negative regulation of mucus secretion                  Not significant
  GO:0070257   GOBP       positive regulation of mucus secretion                  Not significant
  GO:0070701   GOCC       mucus layer                                             Not significant
  GO:0070702   GOCC       inner mucus layer                                       Not significant
  GO:0070703   GOCC       outer mucus layer                                       Not significant
  GO:0006486   GOBP       protein glycosylation                                   Not significant
  GO:0006487   GOBP       protein N-linked glycosylation                          Not significant
  GO:0006493   GOBP       protein O-linked glycosylation                          Not significant
  GO:0006517   GOBP       protein deglycosylation                                 Not significant
  GO:0018242   GOBP       protein O-linked glycosylation via serine               Not significant
  GO:0018243   GOBP       protein O-linked glycosylation via threonine            Not significant
  GO:0018279   GOBP       protein N-linked glycosylation via asparagine           Not significant
  GO:0033575   GOBP       protein glycosylation at cell surface                   Not significant
  GO:0033577   GOBP       protein glycosylation in endoplasmic reticulum          Not significant
  GO:0033578   GOBP       protein glycosylation in Golgi                          Not significant
  GO:0060049   GOBP       regulation of protein glycosylation                     Not significant
  GO:0060050   GOBP       positive regulation of protein glycosylation            Not significant
  GO:0060051   GOBP       negative regulation of protein glycosylation            Not significant
  GO:0090283   GOBP       regulation of protein glycosylation in Golgi            Not significant
  GO:0090284   GOBP       positive regulation of protein glycosylation in Golgi   Not significant
  GO:0090285   GOBP       negative regulation of protein glycosylation in Golgi   Not significant
  5894152      Reactome   O-glycosylation of TSR domain-containing proteins       Not significant
  GO:0070830   GOBP       tight junction assembly                                 Not significant
  GO:1902396   GOBP       protein localization to tight junction                  Not significant
  GO:2000810   GOBP       regulation of tight junction assembly                   Not significant
  GO:0005923   GOCC       tight junction                                          Not significant
  GO:0007045   GOBP       cell-substrate adherens junction assembly               Not significant
  GO:0034332   GOBP       adherens junction organization                          Not significant
  GO:0034333   GOBP       adherens junction assembly                              Not significant
  GO:0034334   GOBP       adherens junction maintenance                           Not significant
  GO:0071896   GOBP       protein localization to adherens junction               Not significant
  GO:0005912   GOCC       adherens junction                                       Not significant
  GO:0005913   GOCC       cell-cell adherens junction                             Not significant
  GO:0005914   GOCC       spot adherens junction                                  Not significant
  GO:0005924   GOCC       cell-substrate adherens junction                        Not significant

Muc2 and MUC2 modifying enzymes -- protein levels in situ:

We also assessed the expression of MUC2 protein as a surrogate of the mucus layer in cIECs, at steady-state. The thickness of the inner MUC-2 layer was similar between *Triaka* and WT ([Author response image 3A and B](#respfig3){ref-type="fig"}). Taken together, these different analyses do not provide evidence for overtly altered or impaired MUC2 expression, modification or function in the *Triaka* versus WT intestine.

![Analysis Mucin-2 (MUC2) layer.\
(**A**) Immunofluorescence for MUC2 (in green) was performed on colon tissue of the indicated strains. Nuclei were visualized with DAPI. Representative pictures are shown (scale bar: 100µm). (**B**) Thickness of the inner mucus layer was measured on MUC2 immunofluorescent stained slides (*n* = 4-5 WT and *Triaka* mice, with 3 individual measurements per mouse).](elife-28366-resp-fig3){#respfig3}

Current explanations for the reduced intestinal barrier in Triaka mice:

Our additional data presented above suggest that the diminished tightness of the *Triaka* intestine is caused by mechanisms different than a direct effect of *Esrp1^Triaka^* on the splicing pattern of tight junction or adherence junction genes, or of *Muc2* or MUC2-modifiers. In addition, the expression of the majority of these genes in IECs is not or only marginally affected by the *Triaka* mutation.

Therefore, the reduced intestinal barrier in *Triaka* mice is likely caused by a combination of the following three parameters:

i\) Epithelial-to-mesenchymal transition (EMT) is a process by which epithelial cell-cell junctions are destabilized and the apical-basal polarity of epithelia is lost (18, 19). ESRP1 is a well-established regulator of EMT (20, 21), and our results provide several lines of evidence for EMT-associated phenotypes in *Triaka* IECs, including decreased proliferative capacity and decreased expression of E-cadherin (an adherens junction protein). Indeed, downregulation of E-cadherin expression helps the destabilization of cell adhesions and the loss of apical-basal polarity to increase cell motility during EMT (18, 22). E-cadherin downregulation is therefore considered a hallmark of EMT (18). Transcription factors regulating EMT that include SNAIL, SLUG, TWIST, and the ZEB family all repress E-cadherin expression during EMT (18). Of note, inhibition of ZEB1/2 promotes tight junction assembly of breast epithelial cells (23). In contrast to these EMT-promoting factors, *ESRP1* expression correlates with that of E-cadherin (24). *ESRP1* overexpression has been reported to prevent EMT, among others by maintaining high levels of E-cadherin and the localization of this protein at cell junctions, while *ESRP1* knockdown induced the opposite effects (25). Given the above-discussed role of E-cadherin for intestinal epithelial integrity, it is thus likely that EMT-driven downregulation of E-cadherin contributes to the diminished intestinal barrier of *Triaka* mice.

ii\) Moreover, we reveal in our study that distinct ESRP1-specific GPR137 isoforms induced different trans-epithelial electrical resistance in monolayers of transduced intestinal epithelial CMT-93 cells. Indeed, CMT-93 cells transduced with *Gpr137_Long* -- the isoform preferentially expressed in *Esrp1^Triaka^* IECs -- displayed lower barrier integrity compared to cells transduced with the *Gpr137_Short* isoform. Thus, we conclude that alteration in the relative frequency of GPR137 isoform partly underlie the defective barrier in *Triaka* mice ([Figure 5](#fig5){ref-type="fig"}).

iii\) In addition to this involvement of reduced E-cadherin expression and altered generation of GPR137 isoforms, there may be other mechanisms contributing to the diminished barrier integrity in *Triaka* mice. For instance, CD44 is also an important regulator of barrier function (26) and a promoter of EMT (25, 27). Moreover, distinct CD44 isoforms were shown to affect the barrier function in endothelial cells (28) and to induce E-cadherin loss at epithelial cell-cell junctions (25). This is already discussed in the manuscript:

"...Besides *Gpr137*, we also revealed other genes with altered splicing patterns in *Triaka* compared with WT cIECs, which likely also contribute to the intestinal phenotype in *Triaka* mice. Among those ESRP1 target genes, *Cd44* is probably the most studied for its intestinal function. CD44 and its isoforms negatively regulate IEC apoptosis ([@bib71]; [@bib34]) and participate in various cellular functions, such as proliferation, adhesion, and migration ([@bib49])."

> 2\) The authors suggest that the ESRP1-mutated tumors are more aggressive and show signs of EMT. This appears to only be supported by an expression analysis of E-cadherin. The existence of EMT features should be supported by the inclusion of additional markers.

To address this point, we compared the expression of additional epithelial and mesenchymal markers commonly used to assess EMT. Analysis of our RNA sequencing data indicated a consistent trend for downregulation or upregulation of several epithelial- or mesenchymal-regulated gene transcripts in *Triaka* compared to WT cIECs, respectively ([Author response image 4A](#respfig4){ref-type="fig"}).

These findings were further validated for several of these markers by qPCR.Expression of the EMT-inducing transcription factors *Zeb1* and *Zeb2* was increased in *Triaka* cIECs ([Author response image 4B-C](#respfig4){ref-type="fig"}). Correspondingly, *Cdh1* and *Esrp1* expression was downregulated in these cells, in agreement with previous studies (24, 25) ([Author response image 1](#respfig1){ref-type="fig"} and [4D](#respfig4){ref-type="fig"}, respectively). In addition, we show in the manuscript that, compared to controls, *Triaka* intestinal tumors display increased expression of TGF-β1 protein, a well-known EMT inducer (32, 33) ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

Taken together, these results indicate a more mesenchymal transcription pattern in *Triaka* cIECs, therefore suggesting that these cells underwent partial EMT. We added this information to the revised main manuscript (see also new figure: [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}):

"...These features of *Esrp1^Triaka^* CRC lesions likely resulted from a partial EMT signature expressed by *Triaka* cIECs, prior to transformation ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"})."

![Partial EMT signature in *Triaka* cIECs.\
(**A**) RNA sequencing was performed on colonic intestinal epithelial cells (cIECs) from *Triaka* and WT mice to assess expression of the indicated epithelial or mesenchymal marker genes (*n* = 4 mice per group). (**B**) Quantitative PCR was applied to measure transcript levels for *Zeb1, Zeb2* (mesenchymal genes) and *Esrp1* (epithelial gene) in WT and *Triaka* cIECs, after normalization to *Gapdh* expression (*n* = 9-14 mice per group). Statistics: (**B**) Student's *t* test. \*, P \< 0.05, \*\*, P \< 0.01.](elife-28366-resp-fig4){#respfig4}

> 3\) The human data, which enriches the vast amount of granular experiments performed in order to study the Esrp1^Triaka^ model, highlight that Esrp1 deserves attention from the community and certainly warrants further studies. For the human data on survival tables, please highlight the patient characteristics and the exclusion of differences that might explain survival benefits.

To specifically address these comments, we first performed a univariate analysis assessing ESRP1 expression or clinicopathological features relatively to patient survival. Parameters found to be statistically significant in this first univariate analysis were subsequently analyzed in a multivariate analysis. In this multivariate analysis, ESRP1 expression was found to be a significant predictor of CRC patient survival when controlling for other confounding factors. We accordingly updated this information in the revised manuscript as follows:

"Furthermore, low nuclear ESRP1 expression was associated with reduced patient survival (*P =* 0.0456), larger tumors (*P =* 0.0034), lymphatic invasion (*P =* 0.0466), advanced pT-stage (*P =* 0.02) and presence of nodal metastasis (*P =* 0.016) ([Figure 6C](#fig6){ref-type="fig"} and [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). ESRP1 expression was determined to be an independent prognostic factor, after adjusting for the confounding effects of pT, pN, pM, tumor budding, and lymphatic invasion ([Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). This indicates a possible tumor-suppressive role of ESRP1 in CRC."

In addition, we added a new table showing the results of the univariate and multivariate survival analysis ([Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}) and we updated the section on "Evaluation of ESRP1 in CRC and IBD cases" in the Materials and methods of the revised manuscript.

> Minor points:
>
> 1\) While the authors clearly show altered expression of two known targets of Esrp1 and decide to study hypofunctional Esrp1 in intestinal epithelial cells, the exact consequence of the Esrp1-M161V substitution and its effects on Esrp1 function remains difficult to determine. Specifically, while both Cd44v5 and Fgfr2-IIIb expression serve as proof-of-principle and are diminished in Esrp1Triaka mice, the degree to which they are diminished differs vastly. Is it possible that reduced function of Esrp1 (albeit to different degrees for each individual target) or potentially additional \'off\'-target effects (modifying some of the 35 identified Ersp1-targets) explain parts of the phenotype. Please expand discussion on these topics.

We presently do not have evidence that off-target effects may be caused by *Esrp1^Triaka^*. Nevertheless, it has to be mentioned here that as many as 14 of the 35 identified genes with different relative frequency of splicing isoforms in *Esrp1^Triaka^*compared to *Esrp1*^WT^ cIECs have been previously reported to be targets of *Esrp1* in tissues other than intestine (15-17, 34). This further supports the notion of a hypomorphic instead of a neomorphic activity (or gain-of-function) of ESRP1*^Triaka^*.

We currently do not have a definitive explanation as to why hypofunctional *Esrp1^Triaka^* has a distinct impact on *Cd44v5* and *Fgfr2*-IIIb splicing. These differences may be reflective of i) non-physiological in vitro conditions, e.g. due to the use of transfected cell lines, ii) target gene-specific effects of *Esrp1^Triaka^* (i.e. exons of transcripts from distinct genes may be spliced by ESRP1 at different rates. Indeed, *Esrp*-regulated splicing events have been reported to show variable sensitivity to the loss of *Esrp1* (and/or *Esrp2*) (15, 24)), iii) or they may also depend on the relative abundance of target pre-mRNA. The latter was observed, e.g., for the splicing of *Fgfr2*-IIIb that was not affected by the *Esrp1^Triaka^* mutation in vivo, at steady-state. Inflammatory conditions upregulate *Fgfr2* expression (35-37), and we accordingly observed an increase in *Fgfr2*-IIIb transcripts in cIECs from mice with mild colitis. Interestingly, these inflammatory conditions also revealed the splicing defects of ESRP1*^Triaka^*, as evidenced by reduced *Fgfr2*-IIIb levels in *Triaka* compared to WT cIECs ([Author response image 5](#respfig5){ref-type="fig"}). Yet these results are preliminary, as it is not known how inflammation may further modulate *Esrp1* expression or function.

![Availability of target transcripts may determine the effect of the *Esrp1^Triaka^* mutation.\
*Fgfr2*-IIIb expression levels were measured in EPCAM^+^-sorted colonic intestinal epithelial cells of the indicated strains and normalized to *Gapdh* expression.\
Intestinal epithelial cells were isolated from mice at steady-state or from animals that underwent a short 3 day-treatment with dextran sodium sulfate (indicated as "Inflammatory conditions") (*n* = 9 mice per group for steady-state conditions and *n* = 7 mice per group during inflammation conditions. Statistics: (**B**) Mann-Whitney test. \*, *P* \< 0.05.](elife-28366-resp-fig5){#respfig5}

We also discuss now these points in the revised manuscript, respectively:

"...ESRP1*^Triaka^* however showed reduced levels of *Cd44v5* and *Fgfr2-*IIIb inclusion, with 1.8 and 3.3 fold induction, respectively ([Figure 1A and B](#fig1){ref-type="fig"}). This variation in the extent of in vitro splicing of *Cd44* versus *Fgfr2* by ESRP1*^Triaka^* likely relates to the fact that *Esrp1*-regulated splicing events show distinct sensitivity to *Esrp1* loss (15, 24)."

"...Although our data indicate reduced splicing activity from the *Triaka* mutation, a possible neomorphic effect of ESRP1*^Triaka^* cannot be fully excluded, and further investigation using other genetic models is required to examine this aspect."

> Reviewer \#1:
>
> \[...\] The following points should be addressed to improve this study:
>
> 1\) Is there any difference in the expression of components of the tight junctions? This would support the authors claim about a barrier defect.

Please refer to Essential Revision \#1 as an answer to this comment.

> 2\) Is there any clear evidence for the existence of EMT apart from changes in E-cadherin?

Please refer to Essential Revision \#2 as an answer to this comment.

> Reviewer \#2:
>
> \[...\] Minor criticism is listed below:
>
> 1\) Increased bacterial translocation and anti-commensal antibody response, but normal fecal albumin, lipocalin and FITC-dextrane permeability may indicate specific defects in mucus. Does Esrp-1 regulate splicing in Muc2 or any enzymes known for modifications/glycosylation of Muc2?
>
> Please refer to Essential Revision \#1 as an answer to this comment.
>
> Reviewer \#3:
>
> \[...\] The major limitation of this study lies in the utilization of the Esrp1^Triaka^ model itself. While clearly the authors show altered expression of two known targets of Esrp1 and conclude therefore to study hypofunctional Esrp1 in intestinal epithelial cells, the exact consequence of the Esrp1-M161V substitution and therefore on Esrp1 function remains difficult to determine. Therefore, the relevance of studying this specific point mutation in the absence of an association with human disease is at least somewhat limited. Specifically, while both Cd44v5 and Fgfr2-IIIb expression that serve as proof of principle are diminished in Esrp1^Triaka^ mice the degree to which they are diminished differs vastly. Therefore it cannot be fully addressed if indeed reduced function of Esrp1 (albeit to different degrees for each individual target) or additional off-target effects (artificially modifying some of the 35 identified Ersp1-targets) explain parts of the phenotype. Have the authors considered at all to study Esrp1 heterozygous KO mice (Esrp1+/-) or mice exhibiting a heterozygous conditional deletion within the intestinal epithelium? Alternatively, a conditional deletion of both alleles at a later time point e.g. 6 weeks of age utilizing e.g. Vcre-ERT2 mice might provide additional insight.

Please refer to Minor Point \#1 as a partial answer to this comment.

Heterozygous ESRP1 knockout (*Esrp1*^+/-^) mice have been reported not to show any phenotype or splicing defects. Specifically, epidermal splicing of *Arhgef11, Enah, Fgfr1-IIIb, or Fgfr3-IIIb* was altered in homozygous *Esrp1*^-/-^ compared to WT mice, yet it was not altered in heterozygous *Esrp1*^+/-^ animals (15). Accordingly, it is unlikely that *Esrp1*^+/-^ mice show an intestinal phenotype.
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